Journal of Clinical Psychiatry

Subject Index to Volume 57: January 1996 Through December 1996

Academic Highlights
Advancements in CNS drugs. July 315–326
Choosing among old and new antipsychotics. Sept 427–438
Controversies in the diagnosis and treatment of severe depression. Nov 554–561
New perspectives in the management of depression. Aug 377–384
Ongoing needs in depression. Dec 600–610
Practical approaches to the treatment of panic disorder. Jan 45–52
Recent developments in neurobiology of obsessive-compulsive disorder. Oct 492–503
Acquired Immune Deficiency Syndrome see AIDS
ADHD see Attention-Deficit/Hyperactivity Disorder
Adolescents
Antipsychotic medications in children and adolescents. Findling, Suppl 9, 19–23
DSM-IV stereotypic movement disorder: persistence of stereotypies of infancy in intellectually normal adolescents and adults. Castellanos, Mar 116–122
Psychoses in children and adolescents: a review. Tolbert, Suppl 3, 4–8
Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience. DeVane, Feb 55–66
Adults
DSM-IV stereotypic movement disorder: persistence of stereotypies of infancy in intellectually normal adolescents and adults. Castellanos, Mar 116–122
Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. Findling, May 184–189
Affective Disorder see also Depression; Mood
Cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. Ghadirian, Jan 22–28
Introduction. Pharmacology of new antidepressants: from the laboratory to the clinic. Leonard, Suppl 4, 3
Use of valproate in an elderly population with affective symptoms. Kando, June 238–240
Aggression
Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients. Allan, Oct 455–459
Agitation
Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: toward a treatment approach. Mintzer, Suppl 7, 55–63
Treating the agitated alzheimer patient. Zayas, Suppl 7, 46–51
Treatment strategies for agitation and psychosis in dementia. Tariot, Suppl 14, 21–29
Zolpidem for the treatment of agitation in elderly demented patients [letter]. Jackson, Aug 372–373
Agoraphobia
Panic disorder and agoraphobia: hypothesis hothouse. Klein, Suppl 6, 21–27
AIDS
Relative contributions of psychiatric symptoms and AIDS knowledge to HIV risk behaviors among people with severe mental illness. McKinnon, Nov 506–513
Akathisia
Fluoxetine-induced akathisia does not reappear after switch to paroxetine [letter]. Bauer, Dec 593–594
Alcohol and Alcoholism
Benzodiazepine use in anxiety disordered patients with and without a history of alcoholism. Mueller, Feb 83–89
Evaluation and treatment of anxiety symptoms and disorders in alcoholics. Kranzler, Suppl 7, 15–21
Review of the effects of moderate alcohol intake on the treatment of anxiety and mood disorders. Castañeda, May 207–212
Alopecia
Fluoxetine-associated paresthesias and alopecia in a woman who tolerated sertraline [letter]. Bhatara, May 227
Alprazolam
Diazepam versus alprazolam for the treatment of panic disorder. Noyes, Aug 349–355
Nefazodone relief of alprazolam interdose dysphoria: a potential therapeutic benefit of 3A3/4 inhibition [letter]. Ketter, July 307
Alzheimer's Disease see also Dementia
Developing treatment guidelines for Alzheimer's disease and other dementias. Rabins, Suppl 14, 37–38
Introduction: clinical developments in Alzheimer's disease. Schneider, Suppl 14, 3–4
Neurobiology of Alzheimer's disease. Peskind, Suppl 14, 5–8
Neuroimaging and genetic assessment for early diagnosis of Alzheimer's disease. Small, Suppl 14, 9–13
New therapeutic approaches to Alzheimer's disease. Schneider, Suppl 14, 30–36
Treating the agitated Alzheimer patient. Zayas, Suppl 7, 46–51
Treatment of depressed demented patients. Alexopoulos, Suppl 14, 14–20
Treatment strategies for agitation and psychosis in dementia. Tariot, Suppl 14, 21–29
Amantadine
Breakthrough panic after amantadine treatment in a Parkinson's disease patient [letter]. Noveske, Aug 374
Anger
Fluoxetine in the treatment of anger: an open clinical trial. Rubey, Sept 398–401
Antidepressants see also specific drugs
Adrenoceptors and serotonin receptor function: relevance to antidepressant mechanisms of action. Potter, Suppl 4, 4–8
Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. Salín-Pascual, Sept 387–389
Antidepressant pharmacotherapy and the treatment of depression in patients with severe traumatic brain injury: a controlled, prospective study. Wroblewski, Dec 582–587
Antidepressants and cognitive impairment in the elderly. Oxman, Suppl 5, 38–44
Antidepressant treatment of binge-eating disorder: research findings and clinical guidelines. Hudson, Suppl 8, 73–79
Coadministration of isoniazid and antidepressant drugs [letter]. Malek-Ahmadi, Nov 550
Efficacy and tolerability of antidepressant therapy in the old-old. Finkel, Suppl 5, 23–28
G protein–mediated signal transduction as a target of antidepressant and antibipolar drug action: evidence from model systems. Rasenick, Suppl 13, 49–55
How do antidepressants affect serotonin receptors? the role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. Goodwin, Suppl 4, 9–13
Introduction. Pharmacology of new antidepressants: from the laboratory to the clinic. Leonard, Suppl 4, 3
New approaches to the treatment of depression. Leonard, Suppl 4, 26–33
Patients excluded from an antidepressant efficacy trial. Partonen, Dec 572–575
Tolerability and safety: essentials in antidepressant pharmacotherapy. Lader, Suppl 2, 39–44
Antipsychotic Drugs see Neuroleptics
Anxiety see also Generalized Anxiety; Mixed Anxiety-Depression
Behavior therapy: endogenous serotonin therapy? Baer, Suppl 6, 33–35

Benzodiazepine use in anxiety disordered patients with and without a history of alcoholism. Mueller, Feb 83–89
Effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. Zajecka, Suppl 2, 10–14
Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. Sramek, July 287–291
Epidemiology and psychopharmacology of anxiety in medical patients. Stoudemire, Suppl 7, 64–72
Evaluation and treatment of anxiety symptoms and disorders in alcoholics. Kranzler, Suppl 7, 15–21
Infrequency of "pure culture" diagnoses among the anxiety disorders. Goldenberg, Nov 528–533
Introduction. Anxiety disorders: the role of serotonin. Greist, Suppl 6, 3–4
Major depression and anxiety disorders associated with Norplant. Wagner, Apr 152–157
Offensive subtype of taijin-kyofu-sho in New York City: the phenomenology and treatment of a social anxiety disorder. Clarvit, Nov 523–527
Relationship between fluoxetine use and suicidal behavior in 654 subjects with anxiety disorders. Warshaw, Apr 158–166
Review of the effects of moderate alcohol intake on the treatment of anxiety and mood disorders. Castañeda, May 207–212
Serotonin receptor specificity in anxiety disorders. Lucki, Suppl 6, 5–10

Anxiolytic Agents

Augmentation strategies: focus on anxiolytics. Joffe, Suppl 7, 25–31

Asystole

Asystole in electroconvulsive therapy: report of four cases. McCall, May 199–203

Atenolol

Sertraline does not alter the β-adrenergic blocking activity of atenolol in healthy male volunteers. Ziegler, Suppl 1, 12–15

Attention-Deficit/Hyperactivity Disorder

Treatment of a 4-year-old boy with ADHD with the dopamine releaser phentermine [letter]. Rothman, July 308–309
Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. Findling, May 184–189

Autism

Sertraline response in adults with mental retardation and autistic disorder. Hellings, Aug 333–336

Behavior Therapy

Behavior therapy: endogenous serotonin therapy? Baer, Suppl 6, 33–35

Benzodiazepines

Benzodiazepine use in anxiety disordered patients with and without a history of alcoholism. Mueller, Feb 83–89
Treatment of recent trauma survivors with benzodiazepines: a prospective study. Gelpin, Sept 390–394

Benztropine

Withdrawal dyskinesia after abrupt cessation of clozapine and benztropine [letter]. Songer, Jan 40

Binge-Eating Disorder

Antidepressant treatment of binge-eating disorder: research findings and clinical guidelines. Hudson, Suppl 8, 73–79

Biology

Biological basis of panic disorder. Krystal, Suppl 10, 23–31

Bipolar Disorder

Antipsychotics in bipolar disorder. Gelenberg, Suppl 9, 49–52
Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. Baldessarini, Oct 441–448
Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. Keck, Apr 147–151
Mania, psychosis, and antipsychotics. McElroy, Suppl 3, 14–26
Pharmacoeconomic model of divalproex vs. lithium in the acute and prophylactic treatment of bipolar I disorder. Keck, May 213–222
Treatment of bipolar disorder [Expert Consensus Guideline Series]. Suppl 12A, 2–89
Use of risperidone in the treatment of bipolar disorder [letter]. Schaffer CB, Mar 136
Verapamil maintenance therapy in bipolar patients [letter]. Giannini, Mar 136

Body Dysmorphic Disorder

Body dysmorphic disorder: diagnosis and treatment of imagined ugliness. Phillips, Suppl 8, 61–64
Spectrum models [letter]. Smith MN; Phillips reply, July 310–311

Books Reviewed

Akhtar S: *Quest for Answers: A Primer of Understanding and Treating Severe Personality Disorders.* Alarcon, Oct 490–491
Andrews G, Crino R, Hunt C, Lampe L, Page A: *The Treatment of Anxiety Disorders: Clinician's Guide and Patient Manuals.* Billings, June 270
Ayd F: *Lexicon of Psychiatry, Neurology & the Neurosciences.* Berlow, July 313
Bloom C, Gitter A, Gutwill S, Kogel L, Zaphiropoulos L: *Eating Problems: A Feminist Psychoanalytic Treatment Model.* Surawicz, Jan 44
Brenner HD, Roder V, Hodel B, Kienzle N, Reed D, Liberman RP: *Integrated Psychological Therapy for Schizophrenic Patients (IPT).* Brown P, Nov 553
Carling PJ: *Return to the Community.* Scott, April 180–181
Chiles JA, Strosahl KD: *The Suicidal Patient: Principles of Assessment, Treatment, and Case Management.* Gold, Mar 139
Chiu E, Ames D (eds): *Functional Psychiatric Disorders of the Elderly.* Bharucha, Oct 491
Cornett C: *Reclaiming the Authentic Self: Dynamic Psychotherapy With Gay Men.* Allen, April 181
Eichelman BS, Hartwig AC (eds): *Patient Violence and the Clinician: Clinical Practice #30.* Brown GP, May 229
Falloon IRH, Fadden G: *Integrated Mental Health Care: A Comprehensive Community-Based Approach.* Alarcon, July 314
First MB, Frances A, Pincus HA: *DSM-IV Handbook of Differential Diagnosis.* Alarcon, Aug 375
Gauld A: *A History of Hypnotism.* Battle, Oct 491
Geller JL, Harris M: *Women of the Asylum: Voices From Behind the Walls, 1840–1945.* Surawicz, April 180
Gordon T, Edwards WS: *Making the Patient Your Partner: Communication Skills for Doctors and Other Caregivers.* Post LL, Nov 552–553
Henderson G: *Social Work Interventions: Helping People of Color.* Kennedy, Sept 426
Hess RE, Stark W (eds): *International Approaches to Prevention in Mental Health and Human Services.* Surawicz, May 230
Higgins GO: *Resilient Adults: Overcoming a Cruel Past.* Weise, May 229– 230
Hoffmann E: *The Drive for Self: Alfred Adler and the Founding of Individual Psychology.* Post LL, July 313–314
Kaysen S: *Girl, Interrupted.* Feder, Jan 44
Kocsis JH, Klein DN (eds): *Diagnosis and Treatment of Chronic Depression.* Alarcon, Nov 551
LaBruzza AL, Mendez-Villarubia JM: *Using DSM-IV: A Clinician's Guide to Psychiatric Diagnosis.* Alarcon, Feb 96
Leenaars AA, Maltsberger JT, Neimeyer RA (eds): *Treatment of Suicidal People.* Battle, Nov 551–552
McManus R, Jennings G (eds): *Structured Exercises for Promoting Family and Group Strengths.* Kirola, Dec 598–599
Ney T (ed): *True and False Allegations of Child Sexual Abuse: Assessment and Case Management.* Surawicz, April 180
Oldham JM, Morris LB: *New Personality Self-Portrait: Why You Think, Work, Love, and Act the Way You Do.* Akhtar, Dec 598
Shur R: *Countertransference Enactments: How Institutions and Therapists Actualize Primitive Internal Worlds.* Allen, Sept 426
Sperry L: *Psychopharmacology and Psychotherapy: Strategies for Maximizing Treatment Outcomes.* Hodo, May 230
Thienhaus OJ: *Manual of Clinical Hospital Psychiatry.* Muñoz RA, June 270
Warner R (ed): *Alternatives to the Hospital for Acute Psychiatric Treatment.* Walker PW, Aug 375–376

Brain

Antidepressant pharmacotherapy and the treatment of depression in patients with severe traumatic brain injury: a controlled, prospective study. Wroblewski, Dec 582–587

Brain Imaging

Neuroimaging and genetic assessment for early diagnosis of Alzheimer's disease. Small, Suppl 14, 9–13
Structural brain scanning in psychiatric patients: a further look. Hollister, June 241–244

Breastfeeding

Paroxetine level in breast milk [letter]. Spigset, Jan 39

Bupropion

Functional status in depressed patients: the relationship to disease severity and disease resolution. Mauskopf, Dec 588–592
Panic associated with combining fluoxetine and bupropion [letter]. Young SJ, Apr 177–178

Buspirone

Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. Sramek, July 287–291

Caffeine

Clozapine levels and caffeine [letter]. Odom-White, Apr 175–176

Capgras' Syndrome

Capgras' and Fregoli's syndromes in one family [letter]. Brown ES, Mar 137–138

Carbamazepine

Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. Rapeport, Suppl 1, 20–23
Dosing strategies and time course of response to antimanic drugs. Bowden, Suppl 13, 4–9
Health-economic implications of the onset of action of antimanic agents. Keck, Suppl 13, 13–18

Introduction: time course of improvement in acute mania and rationale for drug selection. Keck, Suppl 13, 3
MAOI-carbamazepine combination and statistical power [letter]. Blanco-Jerez; Ketter reply, July 311–312
Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain? Lenox, Suppl 13, 23–31
Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. Manji, Suppl 13, 34–46

Cardiorespiratory Problems
Cardiorespiratory problems with clozapine [letter]. Frankenburg; Mintzer reply, Nov 548–549

Carpal Tunnel Syndrome
Trichotillomania and carpal tunnel syndrome [letter]. O'Sullivan, Apr 174

Catatonia
Complications of catatonia [letter]. Carroll, Feb 95

Children
Antipsychotic medications in children and adolescents. Findling, Suppl 9, 19–23
Psychoses in children and adolescents: a review. Tolbert, Suppl 3, 4–8
Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience. DeVane, Feb 55–66

Cholesterol
Effect of fluvoxamine on total serum cholesterol levels during weight reduction. de Zwaan, Aug 346–348

Clomipramine
Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. Szegedi, June 257–264

Clozapine
Bladder dysfunction associated with clozapine therapy [letter]. Frankenburg, Jan 39–40
Cardiorespiratory problems with clozapine [letter]. Frankenburg; Mintzer reply, Nov 548–549
Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. Fuller, Nov 514–518
Clozapine in elderly psychotic patients [letter]. Salzman; Mintzer reply, July 309
Clozapine levels and caffeine [letter]. Odom-White, Apr 175–176
Clozapine treatment in polydipsia and intermittent hyponatremia. Spears, Mar 123–128
Combined use of ECT and clozapine [letter]. Lurie, Feb 94–95
Eosinophilia associated with decreasing neutrophil count in a clozapine-treated patient [letter]. Galletly, Jan 40–41
Medication optimization during clozapine treatment [letter]. Suppes, July 307–308
Near syncope associated with concomitant clozapine and cocaine use [letter]. Hameedi, Aug 371–372
Parotid gland swelling with clozapine [letter]. Patkar, Oct 488
Predictive value of eosinophilia for neutropenia during clozapine treatment. Ames, Dec 579–581
Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. Henderson, Sept 395–397
Withdrawal dyskinesia after abrupt cessation of clozapine and benztropine [letter]. Songer, Jan 40

Cocaine
Cocaine-related obsessive homicidal ideation [letter]. Prenzlauer, Sept 424–425
Near syncope associated with concomitant clozapine and cocaine use [letter]. Hameedi, Aug 371–372

Cognition
Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. Goldberg, Suppl 9, 62–65
Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series. Stoll, Aug 356–359

Cognitive Function
Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol. Williams, Suppl 1, 7–11
Antidepressants and cognitive impairment in the elderly. Oxman, Suppl 5, 38–44
Cognitive function in schizophrenic patients. Tollefson, Suppl 11, 31–39

Cognitive Therapy
Cognitive-behavioral therapy and treatment for late-life depression. Thompson LW, Suppl 5, 29–37

Comorbidity
Comorbidity of depression and panic disorder. Gorman, Suppl 10, 34–41
Comorbidity of posttraumatic stress disorder and irritable bowel syndrome. Irwin, Dec 576–578
Open-label trial of nefazodone in high comorbidity panic disorder. DeMartinis, June 245–248

Compliance
Compliance issues in primary care. Lieberman JA III, Suppl 7, 76–82
Factors associated with pharmacologic noncompliance in patients with mania. Keck, July 292–297

Compulsive Buying
Compulsive buying: a review. Black, Suppl 8, 50–54
Cue exposure in compulsive buying [letter]. Bernik, Feb 90

Correction
Antidepressants and cognitive impairment in the elderly. Oxman, Suppl 5, 38–44; Correction, Aug 374

Cost-Effectiveness see Economics

Crying
Inability to cry during SRI treatment [letter]. Oleshansky, Dec 593

Cytochrome P450
Drug-drug interactions [letter]. Preskorn; DeVane reply, May 223–227
Nefazodone relief of alprazolam interdose dysphoria: a potential therapeutic benefit of 3A3/4 inhibition [letter]. Ketter, July 307
Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. Ereshefsky, Suppl 8, 17–24

Delusions
Delusional disorder: the recognition and management of paranoia. Manschreck, Suppl 3, 32–38
Psychotic depression. Coryell, Suppl 3, 27–31

Dementia see also Alzheimer's Disease
Staging methods for the assessment of dementia: perspectives. Cohen-Mansfield, May 190–198
Treatment of the elderly suffering from psychosis and dementia. Sunderland, Suppl 9, 53–56
Zolpidem for the treatment of agitation in elderly demented patients [letter]. Jackson, Aug 372–373

Depression see also Seasonal Affective Disorder
Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. Salín-Pascual, Sept 387–389
Antidepressant pharmacotherapy and the treatment of depression in patients with severe traumatic brain injury: a controlled, prospective study. Wroblewski, Dec 582–587
Cognitive-behavioral therapy and treatment for late-life depression. Thompson LW, Suppl 5, 29–37
Comorbidity of depression and panic disorder. Gorman, Suppl 10, 34–41
Controversies in the diagnosis and treatment of severe depression [Academic Highlights]. Nov 554–561
Depression after smoking cessation: case reports. Stage, Oct 467–469
Development of major depressive disorder during smoking-cessation treatment. Borrelli, Nov 534–538
Diagnosis and treatment of late-life depression. Rothschild, Suppl 5, 5–11
Effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. Zajecka, Suppl 2, 10–14
Efficacy in long-term treatment of depression. Montgomery, Suppl 2, 24–30
Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. Sramek, July 287–291
Electroconvulsive therapy and resistant depression: clinical implications of seizure threshold. Shapira, Jan 32–38
Functional status in depressed patients: the relationship to disease severity and disease resolution. Mauskopf, Dec 588–592
Introduction. Geropsychiatric advances: new therapies and older patients. Yesavage, Suppl 5, 3–4
Introduction. Pharmacology of new antidepressants: from the laboratory to the clinic. Leonard, Suppl 4, 3
Ketoconazole therapy for atypical depression [letter]. Sovner, May 227–228
Major depression and anxiety disorders associated with Norplant. Wagner, Apr 152–157
Multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. Baldwin, Suppl 2, 46–52
Nefazodone in the treatment of severe, melancholic, and recurrent depression. Marcus, Suppl 2, 19–23
Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. Feiger, Suppl 2, 53–62
New approaches to the treatment of depression. Leonard, Suppl 4, 26–33
New perspectives in the management of depression [Academic Highlights]. Aug 377–384
Noradrenergic and serotonergic abnormalities in depression: stress-induced dysfunction? Dinan, Suppl 4, 14–18
Ongoing needs in depression [Academic Highlights]. Dec 600–610
Open trial of fluvoxamine therapy for panic disorder complicated by depression. Spiegel, Suppl 8, 37–41
Psychotic depression. Coryell, Suppl 3, 27–31
Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. Cohn, Suppl 2, 15–18

Response to an open trial of a second SSRI in major depression. Joffe, Mar 114–115
Therapeutic dose range of nefazodone in the treatment of major depression. Robinson, Suppl 2, 6–9
Treatment of depressed demented patients. Alexopoulos, Suppl 14, 14–20
Use of ECT in treatment of depression in patients with diabetes mellitus [letter]. Weiner; Goodnick reply, Mar 138
Use of serotonin selective reuptake inhibitors in geriatric depression. Newhouse, Suppl 5, 12–22
Desipramine
Sertraline versus desipramine in the treatment of premenstrual syndrome: an open-label trial. Freeman EW, Jan 7–11
Dexamethasone Suppression Test
Dexamethasone suppression test in patients with mood disorders. Rush, Oct 470–484
Diabetes
Use of ECT in treatment of depression in patients with diabetes mellitus [letter]. Weiner; Goodnick reply, Mar 138
Diagnosis
Diagnosis and treatment of late-life depression. Rothschild, Suppl 5, 5–11
Infrequency of "pure culture" diagnoses among the anxiety disorders. Goldenberg, Nov 528–533
Panic disorder: diagnosis, epidemiology, and clinical course. Hirschfeld, Suppl 10, 3–8
Diazepam
Diazepam versus alprazolam for the treatment of panic disorder. Noyes, Aug 349–355
Diet
Making of a user friendly MAOI diet. Gardner, Mar 99–104
Digoxin
Absence of a sertraline-mediated effect on digoxin pharmacokinetics and electrocardiographic findings. Rapeport, Suppl 1, 16–19
Diphenhydramine
Diphenhydramine dependence: a need for awareness [letter]. de Nesnera, Mar 136–137
Divalproex
Generalized edema with risperidone: divalproex sodium treatment [letter]. Baldassano, Sept 422
Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series. Stoll, Aug 356–359
Pharmacoeconomic model of divalproex vs. lithium in the acute and prophylactic treatment of bipolar I disorder. Keck, May 213–222
Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium. Granneman, May 204–206
Randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. McElroy, Apr 142–146
Dopamine
Dopamine D_2 receptor imaging and neuroleptic drug response. Heinz, Suppl 11, 84–88
Dosage
Dosage titration issues [letter]. Cohen JS; Pies reply, Jan 43
Incentive bias? [letter] Gammon; Lane reply, Nemeroff reply, Wheadon reply, June 265–269
Therapeutic dose range of nefazodone in the treatment of major depression. Robinson, Suppl 2, 6–9
Drug Administration Routes
Practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. Wei, July 298–302
Drug-Assisted Interview
Use of midazolam with pulse oximetry in the drug-assisted interview. Marcum, Mar 111–113
Drug Dependence see Substance Abuse
Drug Discontinuation see Withdrawal of Drugs
Drug Interaction
Clozapine levels and caffeine [letter]. Odom-White, Apr 175–176
Drug-drug interactions [letter]. Preskorn; DeVane reply, May 223–227
Drug interaction between risperidone and phenytoin resulting in extrapyramidal symptoms [letter]. Sanderson, Apr 177
Interaction profile of sertraline with commonly prescribed medications. Suppl 1
Introduction. Reducing the risk of drug-drug interactions: a goal of rational drug development. Preskorn, Suppl 1, 3–6
Nefazodone relief of alprazolam interdose dysphoria: a potential therapeutic benefit of 3A3/4 inhibition [letter]. Ketter, July 307
Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium. Granneman, May 204–206
Pharmacokinetics and drug interactions: update for new antipsychotics. Ereshefsky, Suppl 11, 12–25
Drugs, Psychotropic
Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome. Peterson, Suppl 9, 24–34
Epidemiology and psychopharmacology of anxiety in medical patients. Stoudemire, Suppl 7, 64–72
New developments in the pharmacologic treatment of schizoaffective disorder. Keck, Suppl 9, 41–48
Drug Therapy, Combination
Augmentation strategies: focus on anxiolytics. Joffe, Suppl 7, 25–31
Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. Szegedi, June 257–264
MAOI-carbamazepine combination and statistical power [letter]. Blanco-Jerez; Ketter reply, July 311–312
Medication optimization during clozapine treatment [letter]. Suppes, July 307–308
Panic associated with combining fluoxetine and bupropion [letter]. Young SJ, Apr 177–178
Response to risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases [letter]. Berigan, Dec 594–595
Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. Henderson, Sept 395–397
Dysthymia
Fluoxetine treatment of dysthymia in the elderly. Nobler, June 254–256
Full efficacy of SSRI treatment in refractory dysthymia is achieved only after 16 weeks [letter]. Albert, Apr 176
Dystonia
Mandibular dystonia associated with the combination of sertraline and metoclopramide [letter]. Christensen, Dec 596
Economics
Health-economic implications of the onset of action of antimanic agents. Keck, Suppl 13, 13–18
Panic disorder: relationship to high medical utilization, unexplained physical symptoms, and medical costs. Katon, Suppl 10, 11–18
Pharmacoeconomic model of divalproex vs. lithium in the acute and prophylactic treatment of bipolar I disorder. Keck, May 213–222
Pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. Glazer, Aug 337–345
Pharmacoeconomics of antipsychotic drug therapy. Hargreaves, Suppl 9, 66–76
ECT see Electroconvulsive Therapy
Edema
Generalized edema with risperidone: divalproex sodium treatment [letter]. Baldassano, Sept 422
Paroxetine-induced angioedema and tongue swelling [letter]. Mithani, Oct 486
Elderly see also Geriatric Psychiatry
Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: toward a treatment approach. Mintzer, Suppl 7, 55–63
Antidepressants and cognitive impairment in the elderly. Oxman, Suppl 5, 38–44
Clozapine in elderly psychotic patients [letter]. Salzman; Mintzer reply, July 309
Fluoxetine treatment of dysthymia in the elderly. Nobler, June 254–256
Overview of generalized anxiety disorder in the elderly. Schneider, Suppl 7, 34–45
Treatment of the elderly suffering from psychosis and dementia. Sunderland, Suppl 9, 53–56
Use of valproate in an elderly population with affective symptoms. Kando, June 238–240
Zolpidem for the treatment of agitation in elderly demented patients [letter]. Jackson, Aug 372–373
Electrocardiogram
Absence of a sertraline-mediated effect on digoxin pharmacokinetics and electrocardiographic findings. Rapeport, Suppl 1, 16–19
Electroconvulsive Therapy
Asystole in electroconvulsive therapy: report of four cases. McCall, May 199–203
Choosing a dosing strategy for electrical stimulation in ECT [letter]. Petrides; Shapira reply, Oct 487–488
Combined use of ECT and clozapine [letter]. Lurie, Feb 94–95
Electroconvulsive therapy and resistant depression: clinical implications of seizure threshold. Shapira, Jan 32–38
Use of ECT in treatment of depression in patients with diabetes mellitus [letter]. Weiner; Goodnick reply, Mar 138
Eosinophilia
Eosinophilia associated with decreasing neutrophil count in a clozapine-treated patient [letter]. Galletly, Jan 40–41
Predictive value of eosinophilia for neutropenia during clozapine treatment. Ames, Dec 579–581
Ephedrine
Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. Fuller, Nov 514–518
Epidemiology
Generalized anxiety disorder: issues in epidemiology. Brawman-Mintzer, Suppl 7, 3–8
Panic disorder: diagnosis, epidemiology, and clinical course. Hirschfeld, Suppl 10, 3–8
Exclusion Criteria
Patients excluded from an antidepressant efficacy trial. Partonen, Dec 572–575
Extrapyramidal Side Effects
Cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. Ghadirian, Jan 22–28

Drug interaction between risperidone and phenytoin resulting in extrapyramidal symptoms [letter]. Sanderson, Apr 177
EPS with fever versus NMS [letter]. Simpson, Dec 595–596
Fenfluramine
Smoking cessation in a patient being treated with fenfluramine plus phentermine for simple obesity [letter]. Rothman, Feb 92–93
Fluoxetine
Critique of fluoxetine study in PTSD [letter]. Glover, Aug 373–374
Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? Zarate, Feb 67–71
Exercise-induced orgasms associated with fluoxetine treatment of depression [letter]. Ellison, Dec 596–597
Fluoxetine-associated paresthesias and alopecia in a woman who tolerated sertraline [letter]. Bhatara, May 227
Fluoxetine-induced akathisia does not reappear after switch to paroxetine [letter]. Bauer, Dec 593–594
Fluoxetine in the treatment of anger: an open clinical trial. Rubey, Sept 398–401
Fluoxetine treatment of dysthymia in the elderly. Nobler, June 254–256
Fluoxetine withdrawal symptoms [letter]. Berlin, Feb 93–94
Panic associated with combining fluoxetine and bupropion [letter]. Young SJ, Apr 177–178
Relationship between fluoxetine use and suicidal behavior in 654 subjects with anxiety disorders. Warshaw, Apr 158–166
Tardive dyskinesia associated with fluoxetine [letter]. Sandler, Feb 91
Use and tolerability of fluoxetine in geropsychiatric inpatients. Orengo, Jan 12–16
Fluvoxamine
Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. Szegedi, June 257–264
Effect of fluvoxamine on total serum cholesterol levels during weight reduction. de Zwaan, Aug 346–348
Fluvoxamine attenuates panic induced by 35% CO_2 challenge. Pols, Nov 539–542
Fluvoxamine for premenstrual dysphoric disorder: a pilot study. Freeman EW, Suppl 8, 56–59
Open trial of fluvoxamine therapy for panic disorder complicated by depression. Spiegel, Suppl 8, 37–41
Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder. Marmar, Suppl 8, 66–70
Response to risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases [letter]. Berigan, Dec 594–595
Suicidal risk during controlled clinical investigations of fluvoxamine. Letizia, Sept 415–421
Folie à Deux
Shared obsessive-compulsive disorder in a married couple: a new variant of folie à deux? [letter] Torch, Oct 489
Fregoli's Syndrome
Capgras' and Fregoli's syndromes in one family [letter]. Brown ES, Mar 137–138
Gambling
Diagnosis, neurobiology, and treatment of pathological gambling. DeCaria, Suppl 8, 80–83
Pathological gambling in hospitalized substance abusing veterans. Daghestani, Aug 360–363
Generalized Anxiety see also Anxiety; Mixed Anxiety-Depression
Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: toward a treatment approach. Mintzer, Suppl 7, 55–63
Generalized anxiety and mixed anxiety-depression: association with disability and health care utilization. Roy-Byrne, Suppl 7, 86–91
Generalized anxiety disorder: issues in epidemiology. Brawman-Mintzer, Suppl 7, 3–8
Long-term management of generalized anxiety disorder: issues and dilemmas. Schweizer, Suppl 7, 9–12
Overview of generalized anxiety disorder in the elderly. Schneider, Suppl 7, 34–45
Genetics
Neuroimaging and genetic assessment for early diagnosis of Alzheimer's disease. Small, Suppl 14, 9–13
Geriatric Psychiatry see also Elderly
Cognitive-behavioral therapy and treatment for late-life depression. Thompson LW, Suppl 5, 29–37
Diagnosis and treatment of late-life depression. Rothschild, Suppl 5, 5–11
Efficacy and tolerability of antidepressant therapy in the old-old. Finkel, Suppl 5, 23–28
Introduction. Geropsychiatric advances: new therapies and older patients. Yesavage, Suppl 5, 3–4
Use and tolerability of fluoxetine in geropsychiatric inpatients. Orengo, Jan 12–16
Use of serotonin selective reuptake inhibitors in geriatric depression. Newhouse, Suppl 5, 12–22
G Proteins
G protein–mediated signal transduction as a target of antidepressant and antibipolar drug action: evidence from model systems. Rasenick, Suppl 13, 49–55
Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. Manji, Suppl 13, 34–46
Guanfacine
Suppression of nightmares with guanfacine [letter]. Horrigan, Aug 371
Guidelines
Treatment of bipolar disorder [Expert Consensus Guideline Series]. Suppl 12A, 2–89
Treatment of schizophrenia [Expert Consensus Guideline Series]. Suppl 12B, 2–59
Hair Pulling see Trichotillomania
Hallucinations
Psychotic depression. Coryell, Suppl 3, 27–31
Haloperidol
Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol. Williams, Suppl 1, 7–11
Causes of haloperidol discontinuation in patients with Tourette's disorder: management and alternatives. Silva, Mar 129–135
Practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. Wei, July 298–302
Randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. McElroy, Apr 142–146
HIV
Relative contributions of psychiatric symptoms and AIDS knowledge to HIV risk behaviors among people with severe mental illness. McKinnon, Nov 506–513
Homicide
Cocaine-related obsessive homicidal ideation [letter]. Prenzlauer, Sept 424–425
Hospitalization
Relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay. Frye, Jan 17–21
Hyperlithemia
Hyperlithemia correction: an untraditional view [letter]. Schou; Swartz reply, Jan 42–43
Hyponatremia
Clozapine treatment in polydipsia and intermittent hyponatremia. Spears, Mar 123–128
Imipramine
Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. Cohn, Suppl 2, 15–18
Insomnia
Structured psychiatric interview and ambulatory sleep monitoring in young psychophysiological insomniacs. Zucconi, Aug 364–370
Interviews
Structured psychiatric interview and ambulatory sleep monitoring in young psychophysiological insomniacs. Zucconi, Aug 364–370
Irritable Bowel Syndrome
Comorbidity of posttraumatic stress disorder and irritable bowel syndrome. Irwin, Dec 576–578
Isoniazid
Coadministration of isoniazid and antidepressant drugs [letter]. Malek-Ahmadi, Nov 550
Journal of Clinical Psychiatry
Annual appreciation [editorial]. Gelenberg, Jan 5–6
Standing guard [editorial]. Gelenberg, Dec 564–566
Ketoconazole
Ketoconazole therapy for atypical depression [letter]. Sovner, May 227–228
Late Luteal Phase Dysphoric Disorder see Premenstrual Dysphoric Disorder
Light Therapy
Controlled comparison of light box and head-mounted units. Levitt, Mar 105–110
Lithium
Cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. Ghadirian, Jan 22–28
Dosing strategies and time course of response to antimanic drugs. Bowden, Suppl 13, 4–9
Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. Baldessarini, Oct 441–448
Health-economic implications of the onset of action of antimanic agents. Keck, Suppl 13, 13–18
Introduction: time course of improvement in acute mania and rationale for drug selection. Keck, Suppl 13, 3
Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series. Stoll, Aug 356–359
Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain? Lenox, Suppl 13, 23–31
Pharmacoeconomic model of divalproex vs. lithium in the acute and prophylactic treatment of bipolar I disorder. Keck, May 213–222
Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium. Granneman, May 204–206
Regulation of signal transduction pathways by mood-stabilizing agents: implications for the

delayed onset of therapeutic efficacy. Manji, Suppl 13, 34–46
Successful treatment of transvestic fetishism with sertraline and lithium [letter]. Rubenstein, Feb 92
Superiority of lithium over verapamil in mania: a randomized, controlled, single-blind trial. Walton, Nov 543–546
Lyme Borreliosis
Memory functioning in lyme borreliosis. Ravdin, July 282–286
Magnetic Resonance Imaging see Brain Imaging
Maintenance Treatment
Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. Baldessarini, Oct 441–448
Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. Keck, Apr 147–151
Maintenance therapy of persons with schizophrenia. Carpenter, Suppl 9, 10–18
Management of late-life psychosis. Jeste, Suppl 3, 39–45
Management of schizophrenia. Marder, Suppl 3, 9–13
Verapamil maintenance therapy in bipolar patients [letter]. Giannini, Mar 136
Mania
Dosing strategies and time course of response to antimanic drugs. Bowden, Suppl 13, 4–9
Factors associated with pharmacologic noncompliance in patients with mania. Keck, July 292–297
Health-economic implications of the onset of action of antimanic agents. Keck, Suppl 13, 13–18
Introduction: time course of improvement in acute mania and rationale for drug selection. Keck, Suppl 13, 3
Mania associated with risperidone use [letter]. Diaz, Jan 41
Mania, psychosis, and antipsychotics. McElroy, Suppl 3, 14–26
Probable induction of mania by risperidone [letter]. Koek, Apr 174–175
Randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. McElroy, Apr 142–146
Relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay. Frye, Jan 17–21
Risperidone in the treatment of mania. Tohen, June 249–253
Superiority of lithium over verapamil in mania: a randomized, controlled, single-blind trial. Walton, Nov 543–546
MARCKS
Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain? Lenox, Suppl 13, 23–31
Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. Manji, Suppl 13, 34–46
Memory
Memory functioning in lyme borreliosis. Ravdin, July 282–286
Men
Sertraline does not alter the β-adrenergic blocking activity of atenolol in healthy male volunteers. Ziegler, Suppl 1, 12–15
Mental Retardation
Sertraline response in adults with mental retardation and autistic disorder. Hellings, Aug 333–336
Methylphenidate
Methylphenidate and SSRI-induced sexual side effects [letter]. Roeloffs; Stoll reply, Nov 548
Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. Stoll, Feb 72–76
Metoclopramide
Mandibular dystonia associated with the combination of sertraline and metoclopramide [letter]. Christensen, Dec 596
Midazolam
Use of midazolam with pulse oximetry in the drug-assisted interview. Marcum, Mar 111–114
Mirtazapine
Pharmacologic profile of mirtazapine. de Boer, Suppl 4, 19–25
Mixed Anxiety-Depression see also Anxiety
Generalized anxiety and mixed anxiety-depression: association with disability and health care utilization. Roy-Byrne, Suppl 7, 86–91
Monoamine Oxidase Inhibitors
Making of a user friendly MAOI diet. Gardner, Mar 99–104
MAOI-carbamazepine combination and statistical power [letter]. Blanco-Jerez; Ketter reply, July 311–312
Mood
Dexamethasone suppression test in patients with mood disorders. Rush, Oct 470–484
Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain? Lenox, Suppl 13, 23–31
Profile of medically serious suicide attempts. Elliott, Dec 567–571
Review of the effects of moderate alcohol intake on the treatment of anxiety and mood disorders. Castañeda, May 207–212
Movement Disorders
Movement disorders associated with the serotonin selective reuptake inhibitors. Leo, Oct 449–454
Nadolol
Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients. Allan, Oct 455–459
Naltrexone
Misuse of naltrexone [letter]. Measom, Oct 488–489
Naltrexone as a treatment for repetitive self-injurious behavior: an open-label trial. Roth, June 233–237
Treatment of obsessive-compulsive cutting behavior with naltrexone [letter]. Bystritsky, Sept 423–424
Nefazodone
Drug craving and other negative reactions after abrupt substitution of nefazodone for other serotonergic agents [letter]. Castañeda, Oct 485–486
Effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. Zajecka, Suppl 2, 10–14
Introduction: progress with nefazodone. Suppl 2, 3
Multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. Baldwin, Suppl 2, 46–52
Nefazodone and symptoms suggesting neurotoxicity: a case report [letter]. Puzantian, Dec 595
Nefazodone in the treatment of severe, melancholic, and recurrent depression. Marcus, Suppl 2, 19–23
Nefazodone relief of alprazolam interdose dysphoria: a potential therapeutic benefit of 3A3/4 inhibition [letter]. Ketter, July 307
Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. Feiger, Suppl 2, 53–62
Open-label trial of nefazodone in high comorbidity panic disorder. DeMartinis, June 245–248
Priapism: trazodone versus nefazodone [letter]. Pecknold, Nov 547–548
Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. Cohn, Suppl 2, 15–18
Safety profile of nefazodone. Robinson, Suppl 2, 31–38
Therapeutic dose range of nefazodone in the treatment of major depression. Robinson, Suppl 2, 6–9
Neuroanatomy
Functional neuroanatomy of obsessive-compulsive disorder. Trivedi, Suppl 8, 26–35
Neurobiology
Neurobiology of Alzheimer's disease. Peskind, Suppl 14, 5–8
Neuroimaging see Brain Imaging
Neuroleptic Malignant Syndrome
EPS with fever versus NMS [letter]. Simpson, Dec 595–596
Neuroleptics see also specific drugs
Antipsychotic medications in children and adolescents. Findling, Suppl 9, 19–23
Antipsychotics in bipolar disorder. Gelenberg, Suppl 9, 49–52
Atypical antipsychotic drugs and long-term outcome of schizophrenia. Weiden, Suppl 11, 53–60
Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. Lieberman JA, Suppl 11, 68–71
Choosing among old and new antipsychotics [ACADEMIC HIGHLIGHTS]. Sept 427–438
Dopamine D_2 receptor imaging and neuroleptic drug response. Heinz, Suppl 11, 84–88
Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. Goldberg, Suppl 9, 62–65
Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. Keck, Apr 147–151
Mania, psychosis, and antipsychotics. McElroy, Suppl 3, 14–26
Pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. Glazer, Aug 337–345
Pharmacoeconomics of antipsychotic drug therapy. Hargreaves, Suppl 9, 66–76
Pharmacokinetics and drug interactions: update for new antipsychotics. Ereshefsky, Suppl 11, 12–25
Preclinical pharmacology of neuroleptics: focus on new generation compounds. Richelson, Suppl 11, 4–11
Side effect profiles of new antipsychotic agents. Casey, Suppl 11, 40–45
Neurotoxicity
Nefazodone and symptoms suggesting neurotoxicity: a case report [letter]. Puzantian, Dec 595
Neutropenia
Predictive value of eosinophilia for neutropenia during clozapine treatment. Ames, Dec 579–581
Nicotine
Antidepressant effect of transdermal nicotine

patches in nonsmoking patients with major depression. Salín-Pascual, Sept 387–389
Norepinephrine
Adrenoceptors and serotonin receptor function: relevance to antidepressant mechanisms of action. Potter, Suppl 4, 4–8
Noradrenergic and serotonergic abnormalities in depression: stress-induced dysfunction? Dinan, Suppl 4, 14–18
Norplant
Major depression and anxiety disorders associated with Norplant. Wagner, Apr 152–157
Obesity
Smoking cessation in a patient being treated with fenfluramine plus phentermine for simple obesity [letter]. Rothman, Feb 92–93
Obsessive-Compulsive Disorder
Cocaine-related obsessive homicidal ideation [letter]. Prenzlauer, Sept 424–425
Functional neuroanatomy of obsessive-compulsive disorder. Trivedi, Suppl 8, 26–35
Obsessive-compulsive and spectrum disorders: overview and quality of life issues. Hollander, Suppl 8, 3–6
Obsessive-compulsive spectrum disorders in primary care: the possibilities and the pitfalls. Higgins, Suppl 8, 7–9
OCD: where the serotonin selectivity story begins. Pigott, Suppl 6, 11–20
Recent developments in neurobiology of obsessive-compulsive disorder [ACADEMIC HIGHLIGHTS]. Oct 492–503
Response to risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases [letter]. Berigan, Dec 594–595
Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. Saxena, July 303–306
Shared obsessive-compulsive disorder in a married couple: a new variant of folie à deux? [letter] Torch, Oct 489
Spectrum models [letter]. Smith MN; Phillips reply, July 310–311
Summary: new frontiers in OCD spectrum research for psychiatry and primary care. Higgins, Suppl 8, 85–87
Treatment of obsessive-compulsive cutting behavior with naltrexone [letter]. Bystritsky, Sept 423–424
Panic
Biological basis of panic disorder. Krystal, Suppl 10, 23–31
Breakthrough panic after amantadine treatment in a Parkinson's disease patient [letter]. Noveske, Aug 374
Clinical issues in the long-term treatment of panic disorder. Rosenbaum, Suppl 10, 44–48
Comorbidity of depression and panic disorder. Gorman, Suppl 10, 34–41
Diazepam versus alprazolam for the treatment of panic disorder. Noyes, Aug 349–355
Fluvoxamine attenuates panic induced by 35% CO_2 challenge. Pols, Nov 539–542
Open-label trial of nefazodone in high comorbidity panic disorder. DeMartinis, June 245–248
Open trial of fluvoxamine therapy for panic disorder complicated by depression. Spiegel, Suppl 8, 37–41
Panic associated with combining fluoxetine and bupropion [letter]. Young SJ, Apr 177–178
Panic attacks with psychotic features. Galynker, Sept 402–406
Panic disorder and agoraphobia: hypothesis hothouse. Klein, Suppl 6, 21–27
Panic disorder: diagnosis, epidemiology, and clinical course. Hirschfeld, Suppl 10, 3–8
Panic disorder in completed suicide. Henriksson, July 275–281
Panic disorder: relationship to high medical utilization, unexplained physical symptoms, and medical costs. Katon, Suppl 10, 11–18
Practical approaches to the treatment of panic disorder [ACADEMIC HIGHLIGHTS]. Jan 45–52
Role of SSRIs in panic disorder. Sheehan, Suppl 10, 51–58
Paranoia
Delusional disorder: the recognition and management of paranoia. Manschreck, Suppl 3, 32–38
Paresthesias
Fluoxetine-associated paresthesias and alopecia in a woman who tolerated sertraline [letter]. Bhatara, May 227
Parkinson's Disease
Breakthrough panic after amantadine treatment in a Parkinson's disease patient [letter]. Noveske, Aug 374
Paroxetine
Fluoxetine-induced akathisia does not reappear after switch to paroxetine [letter]. Bauer, Dec 593–594
Multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. Baldwin, Suppl 2, 46–52
Paroxetine-induced angioedema and tongue swelling [letter]. Mithani, Oct 486
Paroxetine in social phobia. Mancini, Nov 519–522
Paroxetine level in breast milk [letter]. Spigset, Jan 39
Patient Care
Impact of a smoking ban on a locked psychiatric unit. Haller, Aug 329–332
Pharmacoeconomics see Economics
Pharmacokinetics
Pharmacokinetics and drug interactions: update for new antipsychotics. Ereshefsky, Suppl 11, 12–25
Pharmacology
Pharmacologic profile of mirtazapine. de Boer, Suppl 4, 19–25
Preclinical pharmacology of neuroleptics: focus on new generation compounds. Richelson, Suppl 11, 4–11
Phentermine
Smoking cessation in a patient being treated with fenfluramine plus phentermine for simple obesity [letter]. Rothman, Feb 92–93
Treatment of a 4-year-old boy with ADHD with the dopamine releaser phentermine [letter]. Rothman, July 308–309
Phenytoin
Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. Rapeport, Suppl 1, 24–28
Drug interaction between risperidone and phenytoin resulting in extrapyramidal symptoms [letter]. Sanderson, Apr 177
Phobias
Paroxetine in social phobia. Mancini, Nov 519–522
Social phobia: everyone's disorder? Jefferson, Suppl 6, 28–32
Physicians
Science, empathy, and the disappearing patient [letter]. Dean; Hirschfeld reply, Apr 178–179
Polydipsia
Clozapine treatment in polydipsia and intermittent hyponatremia. Spears, Mar 123–128
Posttraumatic Stress Disorder
Comorbidity of posttraumatic stress disorder and irritable bowel syndrome. Irwin, Dec 576–578
Critique of fluoxetine study in PTSD [letter]. Glover, Aug 373–374
Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder. Marmar, Suppl 8, 66–70
Treatment of recent trauma survivors with benzodiazepines: a prospective study. Gelpin, Sept 390–394
Prediction
Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? Zarate, Feb 67–71
Predictive value of eosinophilia for neutropenia during clozapine treatment. Ames, Dec 579–581
Premenstrual Dysphoric Disorder
Fluvoxamine for premenstrual dysphoric disorder: a pilot study. Freeman EW, Suppl 8, 56–59
Sertraline versus desipramine in the treatment of premenstrual syndrome: an open-label trial. Freeman EW, Jan 7–11
Priapism
Priapism: trazodone versus nefazodone [letter]. Pecknold, Nov 547–548
Primary Care
Compliance issues in primary care. Lieberman, July Suppl 7, 76–82
Obsessive-compulsive spectrum disorders in primary care: the possibilities and the pitfalls. Higgins, Suppl 8, 7–9
Summary: new frontiers in OCD spectrum research for psychiatry and primary care. Higgins, Suppl 8, 85–87
Psychiatry
Incentive bias? [letter] Gammon; Lane reply, Nemeroff reply, Wheadon reply, June 265–269
Science, empathy, and the disappearing patient [letter]. Dean; Hirschfeld reply, Apr 178–179
Psychopharmacology see Drugs, Psychotropic
Psychosis
Clozapine in elderly psychotic patients [letter]. Salzman; Mintzer reply, July 309
Evaluating outcomes of treatments for persons with psychotic disorders. Lehman, Suppl 11, 61–67
Introduction: new strategies for treating psychosis. Pickar, Suppl 11, 3
Management of late-life psychosis. Jeste, Suppl 3, 39–45
Mania, psychosis, and antipsychotics. McElroy, Suppl 3, 14–26
Panic attacks with psychotic features. Galynker, Sept 402–406
Psychoses in children and adolescents: a review. Tolbert, Suppl 3, 4–8
Treatment of the elderly suffering from psychosis and dementia. Sunderland, Suppl 9, 53–56
Treatment strategies for agitation and psychosis in dementia. Tariot, Suppl 14, 21–29
Pulse Oximetry
Use of midazolam with pulse oximetry in the drug-assisted interview. Marcum, Mar 111–114
Risperidone
Clinical experience with risperidone. Marder, Suppl 9, 57–61
Drug interaction between risperidone and phenytoin resulting in extrapyramidal symptoms [letter]. Sanderson, Apr 177
Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. Smith RC, Oct 460–466

Generalized edema with risperidone: divalproex sodium treatment [letter]. Baldassano, Sept 422
Mania associated with risperidone use [letter]. Diaz, Jan 41
Probable induction of mania by risperidone [letter]. Koek, Apr 174–175
Response to risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases [letter]. Berigan, Dec 594–595
Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. Henderson, Sept 395–397
Risperidone as a treatment for Tourette's syndrome. Bruun, Jan 29–31
Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. Saxena, July 303–306
Risperidone-induced ejaculatory and urinary dysfunction [letter]. Madhusoodanan, Nov 549–550
Risperidone in the treatment of mania. Tohen, June 249–253
Use of risperidone in the treatment of bipolar disorder [letter]. Schaffer CB, Mar 136

Safety
Safety profile of nefazodone. Robinson, Suppl 2, 31–38
Tolerability and safety: essentials in antidepressant pharmacotherapy. Lader, Suppl 2, 39–44

Schizoaffective Disorder
New developments in the pharmacologic treatment of schizoaffective disorder. Keck, Suppl 9, 41–48

Schizophrenia
Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients. Allan, Oct 455–459
Advancements in CNS drugs [ACADEMIC HIGHLIGHTS]. July 315–326
Atypical antipsychotic drugs and long-term outcome of schizophrenia. Weiden, Suppl 11, 53–60
Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. Lieberman JA, Suppl 11, 68–71
Cognitive function in schizophrenic patients. Tollefson, Suppl 11, 31–39
Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. Goldberg, Suppl 9, 62–65
Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. Smith RC, Oct 460–466
Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. Lieberman JA, Suppl 9, 5–9
Maintenance therapy of persons with schizophrenia. Carpenter, Suppl 9, 10–18
Management of schizophrenia. Marder, Suppl 3, 9–13
Management of treatment-resistant patients with schizophrenia. Marder, Suppl 11, 26–30
Neuropathology of schizophrenia. Bachus, Suppl 11, 72–83
Pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. Glazer, Aug 337–345
Practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. Wei, July 298–302
Relative contributions of psychiatric symptoms and AIDS knowledge to HIV risk behaviors among people with severe mental illness. McKinnon, Nov 506–513
Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. Henderson, Sept 395–397
Treatment of schizophrenia [Expert Consensus Guideline Series]. Suppl 12B, 2–59
Treatment-resistant schizophrenic patients. Kane JM, Suppl 9, 35–40

Seasonal Affective Disorder
Controlled comparison of light box and head-mounted units in the treatment of seasonal depression. Levitt, Mar 105–110

Self-Esteem
Trichotillomania and self-esteem: a survey of 62 female hair pullers. Soriano, Feb 77–82

Self-Injurious Behavior
Naltrexone as a treatment for repetitive self-injurious behavior: an open-label trial. Roth, June 233–237

Serotonin
Adrenoceptors and serotonin receptor function: relevance to antidepressant mechanisms of action. Potter, Suppl 4, 4–8
Behavior therapy: endogenous serotonin therapy? Baer, Suppl 6, 33–35
Drug craving and other negative reactions after abrupt substitution of nefazodone for other serotonergic agents [letter]. Castañeda, Oct 485–486
Drug-drug interactions [letter]. Preskorn; DeVane reply, May 223–227
Full efficacy of SSRI treatment in refractory dysthymia is achieved only after 16 weeks [letter]. Albert, Apr 176
How do antidepressants affect serotonin receptors? the role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. Goodwin, Suppl 4, 9–13
Inability to cry during SRI treatment [letter]. Oleshansky, Dec 593
Introduction. Anxiety disorders: the role of serotonin. Greist, Suppl 6, 3–4
Methylphenidate and SSRI-induced sexual side effects [letter]. Bartlik, Nov 548
Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. Stoll, Feb 72–76
Movement disorders associated with the serotonin selective reuptake inhibitors. Leo, Oct 449–454
Noradrenergic and serotonergic abnormalities in depression: stress-induced dysfunction? Dinan, Suppl 4, 14–18
OCD: where the serotonin selectivity story begins. Pigott, Suppl 6, 11–20
Panic disorder and agoraphobia: hypothesis hothouse. Klein, Suppl 6, 21–27
Response to an open trial of a second SSRI in major depression. Joffe, Mar 114–115
Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. Saxena, July 303–306
Role of SSRIs in panic disorder. Sheehan, Suppl 10, 51–58
Serotonin dysfunction disorders: a behavioral neurochemistry perspective. Petty, Suppl 8, 11–16
Serotonin receptor specificity in anxiety disorders. Lucki, Suppl 6, 5–10
Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. Ereshefsky, Suppl 8, 17–24
Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience. DeVane, Feb 55–66
Social phobia: everyone's disorder? Jefferson, Suppl 6, 28–32
Spectrum models [letter]. Smith MN; Phillips reply, July 310–311
SSRI withdrawal [letter]. Mareth; Ellison reply, July 310
Use of serotonin selective reuptake inhibitors in geriatric depression. Newhouse, Suppl 5, 12–22

Sertraline
Absence of a sertraline-mediated effect on digoxin pharmacokinetics and electrocardiographic findings. Rapeport, Suppl 1, 16–19
Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. Rapeport, Suppl 1, 20–23
Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. Rapeport, Suppl 1, 24–28
Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol. Williams, Suppl 1, 7–11
Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? Zarate, Feb 67–71
Fluoxetine-associated paresthesias and alopecia in a woman who tolerated sertraline [letter]. Bhatara, May 227
Incentive bias? [letter] Gammon; Lane reply, Nemeroff reply, Wheadon reply, June 265–269
Introduction. Reducing the risk of drug-drug interactions: a goal of rational drug development. Preskorn, Suppl 1, 3–6
Mandibular dystonia associated with the combination of sertraline and metoclopramide [letter]. Christensen, Dec 596
Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. Feiger, Suppl 2, 53–62
Sertraline does not alter the β-adrenergic blocking activity of atenolol in healthy male volunteers. Ziegler, Suppl 1, 12–15
Sertraline response in adults with mental retardation and autistic disorder. Hellings, Aug 333–336
Sertraline versus desipramine in the treatment of premenstrual syndrome: an open-label trial. Freeman EW, Jan 7–11
Stuttering with sertraline [letter]. Brewerton, Feb 90–91
Successful treatment of transvestic fetishism with sertraline and lithium [letter]. Rubenstein, Feb 92

Sexual Behavior
Relative contributions of psychiatric symptoms and AIDS knowledge to HIV risk behaviors among people with severe mental illness. McKinnon, Nov 506–513
Successful treatment of transvestic fetishism with sertraline and lithium [letter]. Rubenstein, Feb 92

Sexual Dysfunction
Risperidone-induced ejaculatory and urinary dysfunction [letter]. Madhusoodanan, Nov 549–550

Sexual Side Effects
Exercise-induced orgasms associated with fluoxetine treatment of depression [letter]. Ellison, Dec 596–597
Methylphenidate and SSRI-induced sexual side effects [letter]. Roeloffs; Stoll reply, Nov 548

Priapism: trazodone versus nefazodone [letter]. Pecknold, Nov 547–548
Sleep
Structured psychiatric interview and ambulatory sleep monitoring in young psychophysiological insomniacs. Zucconi, Aug 364–370
Suppression of nightmares with guanfacine [letter]. Horrigan, Aug 371
Smoking
Depression after smoking cessation: case reports. Stage, Oct 467–469
Development of major depressive disorder during smoking-cessation treatment. Borrelli, Nov 534–538
Impact of a smoking ban on a locked psychiatric unit. Haller, Aug 329–332
Smoking cessation in a patient being treated with fenfluramine plus phentermine for simple obesity [letter]. Rothman, Feb 92–93
Social Phobia see Phobias
SSRI see Serotonin
Stereotypic Movement Disorder
DSM-IV stereotypic movement disorder: persistence of stereotypies of infancy in intellectually normal adolescents and adults. Castellanos, Mar 116–122
Stuttering
Stuttering with sertraline [letter]. Brewerton, Feb 90–91
Substance Abuse see also specific drugs
Diphenhydramine dependence: a need for awareness [letter]. de Nesnera, Mar 136–137
Pathological gambling in hospitalized substance abusing veterans. Daghestani, Aug 360–363
Profile of medically serious suicide attempts. Elliott, Dec 567–571
Suicide
Panic disorder in completed suicide. Henriksson, July 275–281
Profile of medically serious suicide attempts. Elliott, Dec 567–571
Relationship between fluoxetine use and suicidal behavior in 654 subjects with anxiety disorders. Warshaw, Apr 158–166
Suicidal risk during controlled clinical investigations of fluvoxamine. Letizia, Sept 415–421
Sydenham's Chorea
Neuropsychiatric aspects of Sydenham's chorea: a comprehensive review. Moore, Sept 407–414
Syncope
Near syncope associated with concomitant clozapine and cocaine use [letter]. Hameedi, Aug 371–372
Taijin-Kyofu-Sho
Offensive subtype of taijin-kyofu-sho in New York City: the phenomenology and treatment of a social anxiety disorder. Clarvit, Nov 523–527
Tardive Dyskinesia
Cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. Ghadirian, Jan 22–28
Double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. Lohr, Apr 167–173
Tardive dyskinesia associated with fluoxetine [letter]. Sandler, Feb 91
Tolerance
Tolerability and safety: essentials in antidepressant pharmacotherapy. Lader, Suppl 2, 39–44
Tourette's Disorder
Causes of haloperidol discontinuation in patients with Tourette's disorder: management and alternatives. Silva, Mar 129–135
Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome. Peterson, Suppl 9, 24–34
Risperidone as a treatment for Tourette's syndrome. Bruun, Jan 29–31
Trauma see Posttraumatic Stress Disorder
Trazodone
Priapism: trazodone versus nefazodone [letter]. Pecknold, Nov 547–548
Trichotillomania
Characterization and treatment of trichotillomania. Christenson, Suppl 8, 42–47
Trichotillomania and carpal tunnel syndrome [letter]. O'Sullivan, Apr 174
Trichotillomania and self-esteem: a survey of 62 female hair pullers. Soriano, Feb 77–82
Urinary Dysfunction
Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. Fuller, Nov 514–518
Risperidone-induced ejaculatory and urinary dysfunction [letter]. Madhusoodanan, Nov 549–550
Valproate
Dosing strategies and time course of response to antimanic drugs. Bowden, Suppl 13, 4–9
Health-economic implications of the onset of action of antimanic agents. Keck, Suppl 13, 13–18
Introduction: time course of improvement in acute mania and rationale for drug selection. Keck, Suppl 13, 3
Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain? Lenox, Suppl 13, 23–31
Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. Manji, Suppl 13, 34–46
Use of valproate in an elderly population with affective symptoms. Kando, June 238–240
Venlafaxine
Breast pain associated with venlafaxine [letter]. Bhatia, Sept 423
Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. Findling, May 184–189
Verapamil
Superiority of lithium over verapamil in mania: a randomized, controlled, single-blind trial. Walton, Nov 543–546
Verapamil maintenance therapy in bipolar patients [letter]. Giannini, Mar 136
Veterans
Pathological gambling in hospitalized substance abusing veterans. Daghestani, Aug 360–363
Vitamin E
Double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. Lohr, Apr 167–173
Weight
Effect of fluvoxamine on total serum cholesterol levels during weight reduction. de Zwaan, Aug 346–348
Withdrawal of Drugs
Causes of haloperidol discontinuation in patients with Tourette's disorder: management and alternatives. Silva, Mar 129–135
Fluoxetine withdrawal symptoms [letter]. Berlin, Feb 93–94
SSRI withdrawal [letter]. Mareth; Ellison reply, July 310
Withdrawal dyskinesia after abrupt cessation of clozapine and benztropine [letter]. Songer, Jan 40
Women
Trichotillomania and self-esteem: a survey of 62 female hair pullers. Soriano, Feb 77–82
Zinc
Possible risks of long-term zinc supplementation [letter]. Severus, Sept 422–423
Zolpidem
Zolpidem for the treatment of agitation in elderly demented patients [letter]. Jackson, Aug 372–373

Journal of Clinical Psychiatry

Author Index to Volume 57: January 1996 Through December 1996

Abed RT see Baldwin DS
Abrams DB see Borrelli B
Akerman D see Bernik MA
Akhtar S. Review of Oldham JM, Morris LB: *New Personality Self-Portrait: Why You Think. Work, Love, and Act the Way You Do.* Dec 598
Alarcon RD. Review of Akhtar S: *Quest for Answers: A Primer of Understanding and Treating Severe Personality Disorders.* Oct 490
Alarcon RD. Review of Falloon RH, Fadden G: *Integrated Mental Health Care: A Comprehensive Community-Based Approach.* July 314
Alarcon RD. Review of First MB, Frances A, Pincus HA: *DSM-IV Handbook of Differential Diagnosis.* Aug 375
Alarcon RD. Review of Kocsis JH, Klein DN (eds): *Diagnosis and Treatment of Chronic Depression.* Nov 551
Alarcon RD. Review of LaBruzza AL, Mendez-Villarubia JM: *Using DSM-IV: A Clinician's Guide to Psychiatric Diagnosis.* Feb 96
Albert R, Ebert D. Full efficacy of SSRI treatment in refractory dysthymia is achieved only after 16 weeks [letter]. Apr 176
Alexander RC see Patkar AA
Alexopoulos GS. The treatment of depressed demented patients. Suppl 14, 14–20
Allan ER, Alpert M, Sison CE, Citrome L, Laury G, Berman I. Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients. Oct 455–459
Allen DM. Review of Cornett C: *Reclaiming the Authentic Self: Dynamic Psychotherapy With Gay Men.* April 181
Allen DM. Review of Shur R: *Countertransference Enactments: How Institutions and Therapists Actualize Primitive Internal Worlds.* Sept 426
Alpert M see Allan ER
Altshuler LL see Frye MA
Alvir JMJ see Lieberman JA
Amaral JAMS see Bernik MA
Ames D, Wirshing WC, Baker RW, Umbricht DSG, Sun AB, Carter J, Schooler NR, Kane JM, Marder SR. Predictive value of eosinophilia for neutropenia during clozapine treatment. Dec 579–581
Amsterdam JD see Sramek JJ
Annable L see Ghadirian AM
Aquila R see Weiden P
Archibald DG see Robinson DS
Ascher A see Baldwin DS
Bachus SE, Kleinman JE. The neuropathology of schizophrenia. Suppl 11, 72–83
Baer L. Behavior therapy: endogenous serotonin therapy? Suppl 6, 33–35
Baer L see Soriano JL
Baker RW see Ames D
Baldassano CF, Ghaemi SN. Generalized edema with risperidone: divalproex sodium treatment [letter]. Sept 422
Baldessarini RJ, Tondo L, Faedda GL, Suppes TR, Floris G, Rudas N. Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. Oct 441–448
Baldwin DS, Hawley CJ, Abed RT, Maragakis BP, Cox J, Buckingham SA, Pover GH, Ascher A. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. Suppl 2, 46–52
Balistreri TM see Keck PE Jr
Ballenger JC see Irwin C
Barickman J see Silva RR
Barnhill LJ see Horrigan JP
Barr WB see Ravdin LD
Bartlik B see Roeloffs C
Battle AO. Review of Gauld A: *A History of Hypnotism.* Oct 491
Battle AO. Review of Leenaars AA, Maltsberger JT, Neimeyer RA (eds): *Treatment of Suicidal People.* Nov 551
Bauer M, Hellweg R, Baumgartner A. Fluoxetine-induced akathisia does not reappear after switch to paroxetine [letter]. Dec 593–594
Baumgartner A see Bauer M
Baxter LR Jr see Saxena S
Bélanger M-C see Ghadirian A-M
Bennett JA see Keck PE Jr; McElroy SL
Berg L see Cohen-Mansfield J
Berigan TR, Harazin JS. Response to risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases [letter]. Dec 594–595
Berk M see Walton SA
Berlin CS. Fluoxetine withdrawal symptoms [letter]. Feb 93–94
Berlow RR. Review of Ayd F: *Lexicon of Psychiatry, Neurology & the Neurosciences.* July 313
Berman I see Allan ER
Bernik MA, Akerman D, Amaral JAMS, Braun RCDN. Cue exposure in compulsive buying [letter]. Feb 90
Bharucha AJ. Review of Chiu E, Ames D (eds): *Functional Psychiatric Disorders of the Elderly.* Oct 491
Bhatara VS, Gupta S, Freeman JW. Fluoxetine-associated paresthesias and alopecia in a woman who tolerated sertraline [letter]. May 227
Bhatia SC, Gupta S, Theesen KA. Breast pain associated with venlafaxine [letter]. Sept 423
Bhattacharyya A see Smith RC
Bilder R see Lieberman JA
Billings CK. Review of Andrews G, Crino R, Hunt C, Lampe L, Page A: *The Treatment of Anxiety Disorders: Clinician's Guide and Patient Manuals.* June 270
Binder RL see Haller E
Black DW. Compulsive buying: a review. Suppl 8, 50–54
Blanco C see Blanco-Jerez C
Blanco-Jerez C, Robles DE, Gilaberte-Asin I, Blanco C. MAOI-carbamazepine combination and statistical power [letter with reply]. July 311–312
Bonne O see Gelpin E
Bonnema J see Cohen-Mansfield J
Borovicka MC see Fuller MA
Borrelli B, Niaura R, Keuthen NJ, Goldstein MG, DePue JD, Murphy C, Abrams DB. Development of major depressive disorder during smoking-cessation treatment. Nov 534–538
Bowden CL. Dosing strategies and time course of response to antimanic drugs. Suppl 13, 4–9
Brandes D see Gelpin E
Braun RCDN see Bernik MA
Brawman-Mintzer O, Lydiard RB. Generalized anxiety disorder: issues in epidemiology. Suppl 7, 3–8
Brawman-Mintzer O see Mintzer JE
Brener W see Irwin C
Brenner R see Madhusoodanan S
Brewerton TD, Markowitz JS, Keller SG, Cochrane CE. Stuttering with sertraline [letter]. Feb 90–91
Broatch J see Hollander E
Brock CD see Irwin C
Brook S see Walton SA
Brown ES, Thompson R, Suppes T. Capgras' and Fregoli's syndromes in one family [letter]. Mar 137–138
Brown GP. Review of Eichelman BS, Hartwig AC (eds): *Patient Violence and the Clinician: Clinical Practice #30.* May 229

Brown P, Gold DD Jr. Review of Brenner HD, Roder V, Hodel B, Kienzle N, Reed D, Liberman RP: *Integrated Psychological Therapy for Schizophrenic Patients (IPT).* Nov 553
Brown TM see Mareth TR
Bruce TJ see Spiegel DA
Bruun RD, Budman CL. Risperidone as a treatment for Tourette's syndrome. Jan 29–31
Buckingham SA see Baldwin DS
Budman CL see Bruun RD
Burrows GD see Noyes R Jr
Byerly MJ see Christensen RC
Bystritsky A, Strausser BP. Treatment of obsessive-compulsive cutting behavior with naltrexone [letter]. Sept 423–424
Bystritsky A see Saxena S
Cai J see Prenzlauer S
Caligiuri MP see Lohr JB
Callahan AM see Ketter TA
Campana A see Zucconi M
Carleborg L see Spigset O
Carpenter WT Jr. Maintenance therapy of persons with schizophrenia. Suppl 9, 10–18
Carroll BT. Complications of catatonia [letter]. Feb 95
Carter J see Ames D
Carter WP see Hudson JI
Casey DE. Side effect profiles of new antipsychotic agents. Suppl 11, 40–45
Castañeda R, Levy R, Westreich LM, Sussman N. Drug craving and other negative reactions after abrupt substitution of nefazodone for other serotonergic agents [letter]. Oct 485–486
Castañeda R, Sussman N, Westreich L, Levy R, O'Malley M. A review of the effects of moderate alcohol intake on the treatment of anxiety and mood disorders. May 207–212
Castellanos FX, Ritchie GF, Marsh WL, Rapoport JL. DSM-IV stereotypic movement disorder: persistence of stereotypies of infancy in intellectually normal adolescents and adults. Mar 116–122
Castillo J see Kando JC
Castronovo C see Zucconi M
Cavanaugh JH see Granneman GR
Centorrino F see Frankenburg FR; Tohen M
Chakos M see Lieberman JA
Chaney KA see Rasenick MM
Chang W-H see Wei F-C
Charney DS see Krystal JH
Chavez M see Malek-Ahmadi P
Chen G see Manji HK
Chen J see Rasenick MM
Cherkasky S see DeCaria CM
Chmiel JJ see Keck PE Jr
Chouinard G see Ghadirian A-M
Christensen RC, Byerly MJ. Mandibular dystonia associated with the combination of sertraline and metoclopramide [letter]. Dec 596
Christenson GA, Crow SJ. The characterization and treatment of trichotillomania. Suppl 8, 42–47
Chua JW see Smith RC
Citrome L see Allan ER
Clarvit SR, Schneier FR, Liebowitz MR. The offensive subtype of taijin-kyofu-sho in New York City: the phenomenology and treatment of a social anxiety disorder. Nov 523–527
Clements C see Ravdin LD
Coates PE see Rapeport WG
Cochrane CE see Brewerton TD
Cohen GD see Cohen-Mansfield J
Cohen JS. Dosage titration issues [letter with reply]. Jan 43
Cohen-Mansfield J, Reisberg B, Bonnema J, Berg L, Dastoor DP, Pfeffer RI, Cohen GD. Staging methods for the assessment of dementia: perspectives. May 190–198
Cohn CK, Robinson DS, Roberts DL, Schwiderski UE, O'Brien K, Ieni JR. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. Suppl 2, 15–18
Cole JO see Stoll AL; Zarate CA Jr
Contreras SA see Malek-Ahmadi P
Cook BL see Noyes R Jr
Coplan JD see Gorman JM
Cornblatt RR see Wroblewski BA
Coryell W. Psychotic depression. Suppl 3, 27–31
Cournos F see McKinnon K
Covey LS see Stage KB
Cox J see Baldwin DS
Crayton JW see Daghestani AN
Cross M see Rapeport WG
Crow SJ see Christenson GA
Crowley GT see Rush AJ
Cutler NR see Sramek JJ
Daghestani AN, Elenz E, Crayton JW. Pathological gambling in hospitalized substance abusing veterans. Aug 360–363
Daniel W see Silva RR
Dastoor DP see Cohen-Mansfield J
Davidson JRT see Mauskopf JA
Davis LL see Petty F
Dean CE. Science, empathy, and the disappearing resident [letter with reply]. Apr 178–179
de Boer T. The pharmacologic profile of mirtazapine. Suppl 4, 19–25
DeCaria CM, Hollander E, Grossman R, Wong CM, Mosovich SA, Cherkasky S. Diagnosis, neurobiology, and treatment of pathological gambling. Suppl 8, 80–83
de Leon J see Odom-White A
Delgado-Parra V see Salín-Pascual RJ
DeMartinis NA, Schweizer E, Rickels K. An open-label trial of nefazodone in high comorbidity panic disorder. June 245–248
de Nesnera AP. Diphenhydramine dependence: a need for awareness [letter]. Mar 136–137
DePue JD see Borrelli B
Deutsch DN see Krystal JH
Devanand DP see Nobler MS
DeVane CL. Reply to Preskorn SH: Drug-drug interactions [letter]. May 225–227
DeVane CL, Sallee FR. Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience. Feb 55–66
Dewland PM see Rapeport WG
de Zwaan M, Nutzinger DO. Effect of fluvoxamine on total serum cholesterol levels during weight reduction. Aug 346–348
Diamond L see Stoll AL
Diaz SF. Mania associated with risperidone use [letter]. Jan 41
Dinan TG. Noradrenergic and serotonergic abnormalities in depression: stress-induced dysfunction? Suppl 4, 14–18
Eastham JH see Jeste DV
Ebert D see Albert R
Elenz E see Daghestani AN
Elliott AJ, Pages KP, Russo J, Wilson LG, Roy-Byrne PP. A profile of medically serious suicide attempts. Dec 567–571
Ellison JM. Exercise-induced orgasms associated with fluoxetine treatment of depression [letter]. Dec 596–597
Ellison JM. Reply to Mareth TR: SSRI withdrawal [letter]. July 310
Emmanuel N see Rubey RN
Engel NL see Rubenstein EB
Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. Suppl 11, 12–25
Ereshefsky L, Riesenman C, Lam YWF. Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. Suppl 8, 17–24
Ereshefsky L see Glazer WM
Faedda GL see Baldessarini RJ
Falsetti SA see Irwin C
Feder R. Review of Kaysen S: *Girl, Interrupted.* Jan 44
Feiger A, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CS. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. Suppl 2, 53–62
Ferini-Strambi L see Zucconi M
Field MG see Jeste DV
Finch NN see Frye MA
Findling RL, Grcevich SJ, Lopez I, Schulz SC. Antipsychotic medications in children and adolescents. Suppl 9, 19–23
Findling RL, Schwartz MA, Flannery DJ, Manos MJ. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. May 184–189
Fink M see Petrides G
Finkel SI. Efficacy and tolerability of antidepressant therapy in the old-old. Suppl 5, 23–28
Fitzsimons LM see Nobler MS
Flanders WD see Letizia C
Flannery DJ see Findling RL
Floris G see Baldessarini RJ
Fogelman S see Sovner R
Forster PL see Rapeport WG
Frankenburg FR, Kalunian D. Cardiorespiratory problems with clozapine [letter with reply]. Nov 548–549
Frankenburg FR, Kando JC, Centorrino F, Gilbert JM. Bladder dysfunction associated with clozapine therapy [letter]. Jan 39–40
Freeman EW, Rickels K, Sondheimer SJ. Fluvoxamine for premenstrual dysphoric disorder: a pilot study. Suppl 8, 56–59
Freeman EW, Rickels K, Sondheimer SJ, Wittmaack FM. Sertraline versus desipramine in the treatment of premenstrual syndrome: an open-label trial. Jan 7–11
Freeman JW see Bhatara VS
Friedhoff AJ see Silva RR
Froeschl M see Tohen M
Frye MA, Altshuler LL, Szuba MP, Finch NN, Mintz J. The relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay. Jan 17–21
Fuller MA, Borovicka MC, Jaskiw GE, Simon MR, Kwon K, Konicki PE. Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. Nov 514–518
Gabrielli WF see Hellings JA
Galletly C, Wilson D, McEwen S. Eosinophilia associated with decreasing neutrophil count in a clozapine-treated patient [letter]. Jan 40–41
Galli L see Zucconi M

Galynker I, Ieronimo C, Perez-Acquino A, Lee Y, Winston A. Panic attacks with psychotic features. Sept 402–406
Galynker I see Prenzlauer S
Gambini O see Zucconi M
Gammon GD. Incentive bias? [letter with reply]. June 265
Gardner DM, Shulman KI, Walker SE, Tailor SAN. The making of a user friendly MAOI diet. Mar 99–104
Garvey MJ see Noyes R Jr
Gelenberg AJ. Annual appreciation [editorial]. Jan 5–6
Gelenberg AJ. Standing guard [editorial]. Dec 564–566
Gelenberg AJ, Hopkins HS. Antipsychotics in bipolar disorder. Suppl 9, 49–52
Gelpin E, Bonne O, Peri T, Brandes D, Shalev AY. Treatment of recent trauma survivors with benzodiazepines: a prospective study. Sept 390–394
Ghadirian A-M, Annable L, Bélanger M-C, Chouinard G. A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. Jan 22–28
Ghaemi SN see Baldassano CF
Giannini AJ, Loiselle RH. Verapamil maintenance therapy in bipolar patients [letter]. Mar 136
Gierz M see Jeste DV
Gilaberte-Asin I see Blanco-Jerez C
Gilbert JM see Frankenburg FR
Giles DE see Rush AJ
Glassman AH see Stage KB
Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. Aug 337–345
Glover H. Critique of fluoxetine study in PTSD [letter]. Aug 373–374
Goff DC see Henderson DC
Goisman RM see Goldenberg IM
Gold DD Jr. Review of Chiles JA, Strosahl KD: *The Suicidal Patient: Principles of Assessment, Treatment, and Case Management.* Mar 139
Gold DD Jr see Brown P
Goldberg TE, Weinberger DR. Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. Suppl 9, 62–65
Goldenberg IM, White K, Yonkers K, Reich J, Warshaw MG, Goisman RM, Keller MB. The infrequency of "pure culture" diagnoses among the anxiety disorders. Nov 528–533
Goldenberg IM see Mueller TI
Goldstein MG see Borrelli B
Goodnick PJ. Reply to Weiner RD: Use of ECT in treatment of depression in patients with diabetes mellitus [letter]. Mar 138
Goodwin GM. How do antidepressants affect serotonin receptors? the role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. Suppl 4, 9–13
Gordon AL see Mueller TI
Gorfine M see Shapira B
Gorman JM, Coplan JD. Comorbidity of depression and panic disorder. Suppl 10, 34–41
Granneman GR, Schneck DW, Cavanaugh JH, Witt GF. Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium. May 204–206
Grcevich SJ see Findling RL
Greist JH. Introduction. Anxiety disorders: the role of serotonin. Suppl 6, 3–4
Griez EJ see Pols HJ
Grossberg GT see Zayas EM
Grossman R see DeCaria CM
Guido JR see McKinnon K
Gumley G see O'Sullivan RL
Gupta S see Bhatara VS; Bhatia SC
Haller E, McNiel DE, Binder RL. Impact of a smoking ban on a locked psychiatric unit. Aug 329–332
Hameedi FA, Sernyak MJ, Naqvi SA, Kosten TR. Near syncope associated with concomitant clozapine and cocaine use [letter]. Aug 371–372
Harazin JS see Berigan TR
Hardy SA see Robinson DS
Hargreaves WA, Shumway M. Pharmacoeconomics of antipsychotic drug therapy. Suppl 9, 66–76
Harnett-Sheehan K see Sheehan DV
Harris MJ see Jeste DV
Härtter S see Szegedi A
Hauzer RC see Pols HJ
Hawley CJ see Baldwin DS
Hegarty JI see Tohen M
Heikkinen ME see Henriksson MM
Heinz A, Knable MB, Weinberger DR. Dopamine D_2 receptor imaging and neuroleptic drug response. Suppl 11, 84–88
Hellings JA, Kelley LA, Gabrielli WF, Kilgore E, Shah P. Sertraline response in adults with mental retardation and autistic disorder. Aug 333–336
Hellweg R see Bauer M
Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. Sept 395–397
Henke CJ see Keck PE Jr
Henriksson MM, Isometsä ET, Kuoppasalmi KI, Heikkinen ME, Marttunen MJ, Lönnqvist JK. Panic disorder in completed suicide. July 275–281
Herman R see McKinnon K
Hiemke C see Szegedi A
Higgins ES. Obsessive-compulsive spectrum disorders in primary care: the possibilities and the pitfalls. Suppl 8, 7–9
Higgins ES, Hollander E. Summary: new frontiers in OCD spectrum research for psychiatry and primary care. Suppl 8, 85–87
Hilton E see Ravdin LD
Himelein CA see Hollander E
Hirschfeld RMA. Panic disorder: diagnosis, epidemiology, and clinical course. Suppl 10, 3–8
Hirschfeld RMA. Reply to Dean CE: Science, empathy, and the disappearing resident [letter]. Apr 179
Hodo DW. Review of Sperry L: *Psychopharmacology and Psychotherapy: Strategies for Maximizing Treatment Outcomes.* May 230
Hoffman RE see Roth AS
Hollander E, Kwon JH, Stein DJ, Broatch J, Rowland CT, Himelein CA. Obsessive-compulsive and spectrum disorders: overview and quality of life issues. Suppl 8, 3–6
Hollander E see DeCaria CM; Higgins ES
Hollister LE, Shah NN. Structural brain scanning in psychiatric patients: a further look. June 241–244
Hopkins HS see Gelenberg AJ
Hornig-Rohan M see Sramek JJ
Horrigan JP, Barnhill LJ. The suppression of nightmares with guanfacine [letter]. Aug 371
Hsiao JK see Manji HK
Hudson JI, Carter WP, Pope HG Jr. Antidepressant treatment of binge-eating disorder: research findings and clinical guidelines. Suppl 8, 73–79
Hurwitz TA see Mithani H
Ieni JR see Cohn CK
Ieronimo C see Galynker I
Irwin C, Falsetti SA, Lydiard RB, Ballenger JC, Brock CD, Brener W. Comorbidity of posttraumatic stress disorder and irritable bowel syndrome. Dec 576–578
Isometsä ET see Henriksson MM
Jackson CW, Pitner JK, Mintzer JE. Zolpidem for the treatment of agitation in elderly demented patients [letter]. Aug 372–373
Jann MW see Wei F-C
Jaskiw GE see Fuller MA
Jefferson JW. Social phobia: everyone's disorder? Suppl 6, 28–32
Jenike MA see O'Sullivan RL; Soriano JL
Jeste DV, Eastham JH, Lacro JP, Gierz M, Field MG, Harris MJ. Management of late-life psychosis. Suppl 3, 39–45
Jiminez-Genchi A see Salín-Pascual RJ
Joffe RT, Levitt AJ, Sokolov STH. Augmentation strategies: focus on anxiolytics. Suppl 7, 25–31
Joffe RT, Levitt AJ, Sokolov STH, Young LT. Response to an open trial of a second SSRI in major depression. Mar 114–115
Joffe RT see Levitt AJ
Johnson MR see Rubey RN
Jones P see Swartz CM
Joseph AB see Wroblewski BA
Judd FK see Noyes R Jr
Kabel D see Petty F
Kalunian D see Frankenburg FR
Kando JC, Tohen M, Castillo J, Zarate CA Jr. The use of valproate in an elderly population with affective symptoms. June 238–240
Kando JC see Frankenburg FR; Zarate CA Jr
Kane JM. Introduction. Antipsychotic drug therapy: current status. Suppl 9, 3–4
Kane JM. Treatment-resistant schizophrenic patients. Suppl 9, 35–40
Kane JM see Ames D
Kapik B see Letizia C
Kaplan PM see Roeloffs C
Kaplita SB see Robinson DS
Katon W. Panic disorder: relationship to high medical utilization, unexplained physical symptoms, and medical costs. Suppl 10, 11–18
Keck PE Jr. Introduction: time course of improvement in acute mania and rationale for drug selection. Suppl 13, 3
Keck PE Jr, McElroy SL, Bennett JA. Health-economic implications of the onset of action of antimanic agents. Suppl 13, 13–18
Keck PE Jr, McElroy SL, Strakowski SM. New developments in the pharmacologic treatment of schizoaffective disorder. Suppl 9, 41–48
Keck PE Jr, McElroy SL, Strakowski SM, Balistreri TM, Kizer DL, West SA. Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. Apr 147–151
Keck PE Jr, McElroy SL, Strakowski SM, Stanton SP, Kizer DL, Balistreri TM, Bennett JA, Tugrul KC, West SA. Factors associated with pharmacologic noncompliance in patients with mania. July 292–297

Keck PE Jr, Nabulsi AA, Taylor JL, Henke CJ, Chmiel JJ, Stanton SP, Bennett JA. A pharmacoeconomic model of divalproex vs. lithium in the acute and prophylactic treatment of bipolar I disorder. May 213–222
Keck PE Jr see McElroy SL
Keller MB see Goldenberg IM; Mueller TI; Warshaw MG
Keller SG see Brewerton TD
Kelley LA see Hellings JA
Kennedy CL. Review of Henderson G: *Social Work Interventions: Helping People of Color.* Sept 426
Kessler CC see Koek RJ
Ketter TA, Callahan AM, Post RM. Nefazodone relief of alprazolam interdose dysphoria: a potential therapeutic benefit of 3A3/4 inhibition [letter]. July 307
Ketter TA, Post RM, Parekh PI, Worthington K. Reply to Blanco-Jerez C: MAOI-carbamazepine combination and statistical power [letter]. July 312
Keuthen NJ see Borrelli B; O'Sullivan RL
Khatami M see Rush AJ
Kiev A see Feiger A
Kilgore E see Hellings JA
Kim MK see Nobler MS
King EF see Levitt AJ
Kirola DB. Review of McManus R, Jennings G (eds): *Structured Exercises for Promoting Family and Group Strengths.* Dec 598–599
Kizer DL see Keck PE Jr
Klein DF. Panic disorder and agoraphobia: hypothesis hothouse. Suppl 6, 21–27
Kleinman JE see Bachus SE
Knable MB see Heinz A
Kocsis JH see Roeloffs C
Koek RJ, Kessler CC. Probable induction of mania by risperidone [letter]. Apr 174–175
Konicki PE see Fuller MA
Koreen AR see Lieberman JA
Kosten TR see Hameedi FA
Kramer GL see Petty F
Kranzler HR. Evaluation and treatment of anxiety symptoms and disorders in alcoholics. Suppl 7, 15–21
Krystal JH, Deutsch DN, Charney DS. The biological basis of panic disorder. Suppl 10, 23–31
Kunik ME see Orengo CA
Kuoppasalmi KI see Henriksson MM
Kwon JH see Hollander E
Kwon K see Fuller MA
Labbate LA see Oleshansky MA
Lacro JP see Jeste DV
Lader MH. Tolerability and safety: essentials in antidepressant pharmacotherapy. Suppl 2, 39–44
Lam YWF see Ereshefsky L
Lane RM. Incentive bias? [letter with reply]. June 265–267
Langer SF see Pecknold JC
Laury G see Allan ER
Leadbetter RA see Spears NM
Leal M see Szegedi A
Lee Y see Galynker I
Lehman AF. Evaluating outcomes of treatments for persons with psychotic disorders. Suppl 11, 61–67
Lenox RH, McNamara RK, Watterson JM, Watson DG. Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain? Suppl 13, 23–31
Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. Oct 449–454
Leonard BE. Introduction. Pharmacology of new antidepressants: from the laboratory to the clinic. Suppl 4, 3
Leonard BE. New approaches to the treatment of depression. Suppl 4, 26–33
Lerer B see Shapira B
Letizia C, Kapik B, Flanders WD. Suicidal risk during controlled clinical investigations of fluvoxamine. Sept 415–421
Levitt AJ, Wesson VA, Joffe RT, Maunder RG, King EF. A controlled comparison of light box and head-mounted units in the treatment of seasonal depression. Mar 105–110
Levitt AJ see Joffe RT
Levy R see Castañeda R
Lidsky D see Shapira B
Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. Suppl 11, 68–71
Lieberman JA, Koreen AR, Chakos M, Sheitman B, Woerner M, Alvir JMJ, Bilder R. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. Suppl 9, 5–9
Lieberman JA III. Compliance issues in primary care. Suppl 7, 76–82
Liebowitz MR see Clarvit SR
Lin H-N see Wei F-C
Lipetsker B see Smith RC
Locke CA see Stoll AL
Lohr JB, Caligiuri MP. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. Apr 167–173
Loiselle RH see Giannini AJ
Lönnqvist JK see Henriksson MM; Partonen T
Lopez I see Findling RL
Lucki I. Serotonin receptor specificity in anxiety disorders. Suppl 6, 5–10
Lurie SN. Combined use of ECT and clozapine [letter]. Feb 94–95
Lydiard RB see Brawman-Mintzer O; Irwin C; Rubey RN
Madhusoodanan S, Brenner R. Risperidone-induced ejaculatory and urinary dysfunction [letter]. Nov 549–550
Malek-Ahmadi P, Chavez M, Contreras SA. Coadministration of isoniazid and antidepressant drugs [letter]. Nov 550
Mancini C, Van Ameringen M. Paroxetine in social phobia. Nov 519–522
Manji HK, Chen G, Hsiao JK, Risby ED, Masana MI, Potter WZ. Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. Suppl 13, 34–46
Manos MJ see Findling RL
Manschreck TC. Delusional disorder: the recognition and management of paranoia. Suppl 3, 32–38
Maragakis BP see Baldwin DS
Marcum JM. The use of midazolam with pulse oximetry in the drug-assisted interview. Mar 111–113
Marcus RN, Mendels J. Nefazodone in the treatment of severe, melancholic, and recurrent depression. Suppl 2, 19–23
Marcus RN see Robinson DS
Marder SR. Clinical experience with risperidone. Suppl 9, 57–61
Marder SR. Management of schizophrenia. Suppl 3, 9–13
Marder SR. Management of treatment-resistant patients with schizophrenia. Suppl 11, 26–30
Marder SR see Ames D
Mareth TR, Brown TM. SSRI withdrawal [letter with reply]. July 310
Markowitz JS see Brewerton TD
Marmar CR, Schoenfeld F, Weiss DS, Metzler T, Zatzick D, Wu R, Smiga S, Tecott L, Neylan T. Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder. Suppl 8, 66–70
Marriott P see Noyes R Jr
Marsh WL see Castellanos FX
Marttunen MJ see Henriksson MM
Masana MI see Manji HK
Maunder RG see Levitt AJ
Mauskopf JA, Simeon GP, Miles MA, Westlund RE, Davidson JRT. Functional status in depressed patients: the relationship to disease severity and disease resolution. Dec 588–592
Mayer PV see Stoll AL
McCall WV. Asystole in electroconvulsive therapy: report of four cases. May 199–203
McElroy SL, Keck PE Jr, Stanton SP, Tugrul KC, Bennett JA, Strakowski SM. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. Apr 142–146
McElroy SL, Keck PE Jr, Strakowski SM. Mania, psychosis, and antipsychotics. Suppl 3, 14–26
McElroy SL see Keck PE Jr
McEwen S see Galletly C
McKinnon K, Cournos F, Sugden R, Guido JR, Herman R. The relative contributions of psychiatric symptoms and AIDS knowledge to HIV risk behaviors among people with severe mental illness. Nov 506–513
McNally RJ see Soriano JL
McNamara RK see Lenox RH
McNiel DE see Haller E
Measom MO. Misuse of naltrexone [letter]. Oct 488–489
Meijer JA see Pols HJ
Mendels J see Marcus RN
Metzler T see Marmar CR
Miles MA see Mauskopf JA
Mintz J see Frye MA
Mintzer JE, Brawman-Mintzer O. Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: toward a treatment approach. Suppl 7, 55–63
Mintzer JE, Pitner JK. Reply to Frankenburg FR: Cardiorespiratory problems with clozapine [letter]. Nov 549
Mintzer JE, Pitner JK. Reply to Salzman C: Clozapine in elderly psychotic patients [letter]. July 310
Mintzer JE see Jackson CW
Mithani H, Hurwitz TA. Paroxetine-induced angioedema and tongue swelling [letter]. Oct 486
Molinari V see Orengo CA
Montgomery SA. Efficacy in long-term treatment of depression. Suppl 2, 24–30
Moore DP. Neuropsychiatric aspects of Sydenham's chorea: a comprehensive review. Sept 407–414
Mosovich SA see DeCaria CM

Mueller TI, Goldenberg IM, Gordon AL, Keller MB, Warshaw MG. Benzodiazepine use in anxiety disordered patients with and without a history of alcoholism. Feb 83–89
Muirhead DC see Rapeport WG
Muñoz DM see Silva RR
Muñoz RA. Review of Thienhaus OJ: *Manual of Clinical Hospital Psychiatry.* June 270
Murphy C see Borrelli B
Nabulsi AA see Keck PE Jr
Naqvi SA see Hameedi FA
Nasrallah HA. Introduction. Psychotic disorders: many forms, common themes. Suppl 3, 3
Nemeroff CB. Reply to Gammon GD; Lane RM: Incentive bias? [letter] June 267–269
Newhouse PA. Use of serotonin selective reuptake inhibitors in geriatric depression. Suppl 5, 12–22
Neylan T see Marmar CR
Niaura R see Borrelli B
Nobler MS, Devanand DP, Kim MK, Fitzsimons LM, Singer TM, Turret N, Sackeim HA, Roose SP. Fluoxetine treatment of dysthymia in the elderly. June 254–256
Norman TR see Noyes R Jr
Norström Å see Spigset O
Noveske FG. Breakthrough panic after amantadine treatment in a Parkinson's disease patient [letter]. Aug 374
Noyes R Jr, Burrows GD, Reich JH, Judd FK, Garvey MJ, Norman TR, Cook BL, Marriott P. Diazepam versus alprazolam for the treatment of panic disorder. Aug 349–355
Nutzinger DO see de Zwaan M
O'Brien K see Cohn CK
Odom-White A, de Leon J. Clozapine levels and caffeine [letter]. Apr 175–176
Oepen G see Severus WE
Oleshansky MA, Labbate LA. Inability to cry during SRI treatment [letter]. Dec 593
Oliver SD see Williams SA
O'Malley M see Castañeda R
Orengo CA, Kunik ME, Molinari V, Workman RH. The use and tolerability of fluoxetine in geropsychiatric inpatients. Jan 12–16
Orsulak PJ see Rush AJ
Ostroff RB see Roth AS
O'Sullivan RL, Keuthen NJ, Jenike MA, Gumley G. Trichotillomania and carpal tunnel syndrome [letter]. Apr 174
O'Sullivan RL see Soriano JL
Oxman TE. Antidepressants and cognitive impairment in the elderly. Suppl 5, 38–44. Correction, Aug 374
Pages KP see Elliott AJ
Parekh PI see Ketter TA
Parker CR Jr see Rush AJ
Partonen T, Sihvo S, Lönnqvist JK. Patients excluded from an antidepressant efficacy trial. Dec 572–575
Patkar AA, Alexander RC. Parotid gland swelling with clozapine [letter]. Oct 488
Pecknold JC, Langer SF. Priapism: trazodone versus nefazodone [letter]. Nov 547–548
Perez-Acquino A see Galynker I
Peri T see Gelpin E
Peskind ER. Neurobiology of Alzheimer's disease. Suppl 14, 5–8
Peterson BS. Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome. Suppl 9, 24–34
Petrides G, Fink M. Choosing a dosing strategy for electrical stimulation in ECT [letter with reply]. Oct 487
Petty F, Davis LL, Kabel D, Kramer GL. Serotonin dysfunction disorders: a behavioral neurochemistry perspective. Suppl 8, 11–16
Pfeffer RI see Cohen-Mansfield J
Phillips KA. Body dysmorphic disorder: diagnosis and treatment of imagined ugliness. Suppl 8, 61–64
Phillips KA. Reply to Smith MN: Spectrum models [letter]. July 311
Phillips KA see Soriano JL
Piao-Chien C see Wei F-C
Pickar D. Introduction: new strategies for treating psychosis. Suppl 11, 3
Pies RW. Reply to Cohen JS: Dosage titration issues [letter]. Jan 43
Pigott TA. OCD: where the serotonin selectivity story begins. Suppl 6, 11–20
Pillay SS see Stoll AL
Pitner JK see Jackson CW; Mintzer JE
Pollack MH see Rosenbaum JF
Pollock RA see Rosenbaum JF
Pols HJ, Hauzer RC, Meijer JA, Verburg K, Griez EJ. Fluvoxamine attenuates panic induced by 35% CO_2 challenge. Nov 539–542
Pope HG Jr see Hudson JI
Post LL. Review of Gordon T, Edwards WS: *Making the Patient Your Partner: Communication Skills for Doctors and Other Caregivers.* Nov 552
Post LL. Review of Hoffmann E: *The Drive for Self: Alfred Adler and the Founding of Individual Psychology.* July 314
Post RM see Ketter TA
Potter WZ. Adrenoceptors and serotonin receptor function: relevance to antidepressant mechanisms of action. Suppl 4, 4–8
Potter WZ see Manji HK
Pover GH see Baldwin DS
Prenzlauer S, Galynker I, Cai J. Cocaine-related obsessive homicidal ideation [letter]. Sept 424–425
Preskorn SH. Drug-drug interactions [letter with reply]. May 223–225
Preskorn SH. Introduction. Reducing the risk of drug-drug interactions: a goal of rational drug development. Suppl 1, 3–6
Primeau M see Ravdin LD
Puzantian T, Shaw RJ. Nefazodone and symptoms suggesting neurotoxicity: a case report [letter]. Dec 595
Rabins PV. Developing treatment guidelines for Alzheimer's disease and other dementias. Suppl 14, 37–38
Rapeport WG, Coates PE, Dewland PM, Forster PL. Absence of a sertraline-mediated effect on digoxin pharmacokinetics and electrocardiographic findings. Suppl 1, 16–19
Rapeport WG, Muirhead DC, Williams SA, Cross M, Wesnes K. Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. Suppl 1, 24–28
Rapeport WG, Williams SA, Muirhead DC, Dewland PM, Tanner T, Wesnes K. Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. Suppl 1, 20–23
Rapeport WG see Williams SA
Rapoport JL see Castellanos FX
Rasenick MM, Chaney KA, Chen J. G protein–mediated signal transduction as a target of antidepressant and antibipolar drug action: evidence from model systems. Suppl 13, 49–55
Ravdin LD, Hilton E, Primeau M, Clements C, Barr WB. Memory functioning in lyme borreliosis. July 282–286
Reich JH see Goldenberg IM; Noyes R Jr
Reisberg B see Cohen-Mansfield J
Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. Suppl 11, 4–11
Rickels K see DeMartinis NA; Freeman EW; Schweizer E
Riesenman C see Ereshefsky L
Risby ED see Manji HK
Ritchie GF see Castellanos FX
Rivera-Meza BL see Salín-Pascual RJ
Roberts DL see Cohn CK; Robinson DS
Robinson DS, Marcus RN, Archibald DG, Hardy SA. Therapeutic dose range of nefazodone in the treatment of major depression. Suppl 2, 6–9
Robinson DS, Roberts DL, Smith JM, Stringfellow JC, Kaplita SB, Seminara JA, Marcus RN. The safety profile of nefazodone. Suppl 2, 31–38
Robinson DS see Cohn CK
Robles DE see Blanco-Jerez C
Roeloffs C, Bartlik B, Kaplan PM, Kocsis JH. Methylphenidate and SSRI-induced sexual side effects [letter with reply]. Nov 548
Roose SP see Nobler MS
Rosas M see Salín-Pascual RJ
Rosenbaum JF, Pollack MH, Pollock RA. Clinical issues in the long-term treatment of panic disorder. Suppl 10, 44–48
Roth AS, Ostroff RB, Hoffman RE. Naltrexone as a treatment for repetitive self-injurious behavior: an open-label trial. June 233–237
Rothman RB. Smoking cessation in a patient being treated with fenfluramine plus phentermine for simple obesity [letter]. Feb 92–93
Rothman RB. Treatment of a 4-year-old boy with ADHD with the dopamine releaser phentermine [letter]. July 308–309
Rothschild AJ. The diagnosis and treatment of late-life depression. Suppl 5, 5–11
Rowland CT see Hollander E
Roy-Byrne PP. Generalized anxiety and mixed anxiety-depression: association with disability and health care utilization. Suppl 7, 86–91
Roy-Byrne PP see Elliott AJ
Rubenstein EB, Engel NL. Successful treatment of transvestic fetishism with sertraline and lithium [letter]. Feb 92
Rubey RN, Johnson MR, Emmanuel N, Lydiard RB. Fluoxetine in the treatment of anger: an open clinical trial. Sept 398–401
Rudas N see Baldessarini RJ
Rush AJ, Giles DE, Schlesser MA, Orsulak PJ, Parker CR Jr, Weissenburger JE, Crowley GT, Khatami M, Vasavada N. The dexamethasone suppression test in patients with mood disorders. Oct 470–484
Rush AJ see Suppes T
Russo J see Elliott AJ
Sackeim HA see Nobler MS
Saeed SA see Spiegel DA
Salín-Pascual RJ, Rosas M, Jiminez-Genchi A, Rivera-Meza BL, Delgado-Parra V. Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. Sept 387–389
Sallee FR see DeVane CL
Salzman C. Clozapine in elderly psychotic patients [letter with reply]. July 309–310

Sanderson DR. Drug interaction between risperidone and phenytoin resulting in extrapyramidal symptoms [letter]. Apr 177
Sandler NH. Tardive dyskinesia associated with fluoxetine [letter]. Feb 91
Sandlund M see Spigset O
Saxena S, Wang D, Bystritsky A, Baxter LR Jr. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. July 303–306
Scarone S see Zucconi M
Schaffer CB, Schaffer LC. The use of risperidone in the treatment of bipolar disorder [letter]. Mar 136
Schaffer LC see Schaffer CB
Schlesser MA see Rush AJ
Schneck DW see Granneman GR
Schneider LS. New therapeutic approaches to Alzheimer's disease. Suppl 14, 30–36
Schneider LS. Overview of generalized anxiety disorder in the elderly. Suppl 7, 34–45
Schneider LS, Small GW. Introduction: clinical developments in Alzheimer's disease. Suppl 14, 3–4
Schneier FR see Clarvit SR
Schoenfeld F see Marmar CR
Schooler NR see Ames D
Schou M. Hyperlithemia correction: an untraditional view [letter with reply]. Jan 42
Schulte HM see Songer DA
Schulz SC see Findling RL
Schwartz MA see Findling RL
Schweizer E, Rickels K. The long-term management of generalized anxiety disorder: issues and dilemmas. Suppl 7, 9–12
Schweizer E see DeMartinis NA
Schwiderski UE see Cohn CK
Scott AM. Review of Carling PJ: *Return to the Community.* April 180–181
Seminara JA see Robinson DS
Sernyak MJ see Hameedi FA
Severus WE, Oepen G, Stoll AL. Possible risks of long-term zinc supplementation [letter]. Sept 422–423
Shah NN see Hollister LE
Shah P see Hellings JA
Shalev AY see Gelpin E
Shapira B, Lerer B. Reply to Petrides G: Choosing a dosing strategy for electrical stimulation in ECT [letter]. Oct 487–488
Shapira B, Lidsky D, Gorfine M, Lerer B. Electroconvulsive therapy and resistant depression: clinical implications of seizure threshold. Jan 32–38
Shaw RJ see Puzantian T
Sheehan DV, Harnett-Sheehan K. The role of SSRIs in panic disorder. Suppl 10, 51–58
Sheitman B see Lieberman JA
Shrivastava RK see Feiger A
Shulman KI see Gardner DM
Shumway M see Hargreaves WA
Shutty MS Jr see Spears NM
Sibert TE see Weiner RD
Sihvo S see Partonen T
Silva RR, Muñoz DM, Daniel W, Barickman J, Friedhoff AJ. Causes of haloperidol discontinuation in patients with Tourette's disorder: management and alternatives. Mar 129–135
Simeon GP see Mauskopf JA
Simon MR see Fuller MA
Simpson GM. EPS with fever versus NMS [letter]. Dec 595–596
Singer TM see Nobler MS
Sison CE see Allan ER
Small GW. Neuroimaging and genetic assessment for early diagnosis of Alzheimer's disease. Suppl 14, 9–13
Small GW see Schneider LS
Smiga S see Marmar CR
Smirne S see Zucconi M
Smith JM see Robinson DS
Smith MN. Spectrum models [letter with reply]. July 310–311
Smith RC, Chua JW, Lipetsker B, Bhattacharyya A. Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. Oct 460–466
Sokolov STH see Joffe RT
Sondheimer SJ see Freeman EW
Songer DA, Schulte HM. Withdrawal dyskinesia after abrupt cessation of clozapine and benztropine [letter]. Jan 40
Soriano JL, O'Sullivan RL, Baer L, Phillips KA, McNally RJ, Jenike MA. Trichotillomania and self-esteem: a survey of 62 female hair pullers. Feb 77–82
Sovner R, Fogelman S. Ketoconazole therapy for atypical depression [letter]. May 227–228
Spears NM, Leadbetter RA, Shutty MS Jr. Clozapine treatment in polydipsia and intermittent hyponatremia. Mar 123–128
Spiegel DA, Saeed SA, Bruce TJ. An open trial of fluvoxamine therapy for panic disorder complicated by depression. Suppl 8, 37–41
Spigset O, Carleborg L, Norström Å, Sandlund M. Paroxetine level in breast milk [letter]. Jan 39
Sramek JJ, Tansman M, Suri A, Hornig-Rohan M, Amsterdam JD, Stahl SM, Weisler RH, Cutler NR. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. July 287–291
Stage KB, Glassman AH, Covey LS. Depression after smoking cessation: case reports. Oct 467–469
Stahl SM see Sramek JJ
Standard J see Weiden P
Stanton SP see Keck PE Jr; McElroy SL
Stein DJ see Hollander E
Stoll AL, Locke CA, Vuckovic A, Mayer PV. Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series. Aug 356–359
Stoll AL, Pillay SS, Diamond L, Workum SB, Cole JO. Reply to Roeloffs C: Methylphenidate and SSRI-induced sexual side effects [letter]. Nov 548
Stoll AL, Pillay SS, Diamond L, Workum SB, Cole JO. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. Feb 72–76
Stoll AL see Severus WE
Stoudemire A. Epidemiology and psychopharmacology of anxiety in medical patients. Suppl 7, 64–72
Strakowski SM see Keck PE Jr; McElroy SL
Strausser BP see Bystritsky A
Stringfellow JC see Robinson DS
Sugden R see McKinnon K
Sun AB see Ames D
Sunderland T. Treatment of the elderly suffering from psychosis and dementia. Suppl 9, 53–56
Suppes T, Rush AJ. Medication optimization during clozapine treatment [letter]. July 307–308
Suppes TR see Baldessarini RJ; Brown ES
Surawicz FG. Review of Bloom C, Gitter A, Gutwill S, Kogel L, Zaphiropoulos L: *Eating Problems: A Feminist Psychoanalytic Treatment Model.* Jan 44
Surawicz FG. Review of Geller JL, Harris M: *Women of the Asylum: Voices From Behind the Walls, 1840–1945.* April 180
Surawicz FG. Review of Hess RE, Stark W (eds): *International Approaches to Prevention in Mental Health and Human Services.* May 230
Surawicz FG. Review of Ney T (ed): *True and False Allegations of Child Sexual Abuse: Assessment and Case Management.* April 180
Suri A see Sramek JJ
Sussman N see Castañeda R
Swartz CM, Jones P. Reply to Schou M: Hyperlithemia correction: an untraditional view [letter]. Jan 42–43
Szegedi A, Wetzel H, Leal M, Härtter S, Hiemke C. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. June 257–264
Szuba MP see Frye MA
Tailor SAN see Gardner DM
Tanner T see Rapeport WG
Tansman M see Sramek JJ
Tariot PN. Treatment strategies for agitation and psychosis in dementia. Suppl 14, 21–29
Taylor JL see Keck PE Jr
Tecott L see Marmar CR
Theesen KA see Bhatia SC
Thompson LW. Cognitive-behavioral therapy and treatment for late-life depression. Suppl 5, 29–37
Thompson R see Brown ES
Tohen M, Zarate CA Jr, Centorrino F, Hegarty JI, Froeschl M, Zarate SB. Risperidone in the treatment of mania. June 249–253
Tohen M see Kando JC; Zarate CA Jr
Tolbert HA. Psychoses in children and adolescents: a review. Suppl 3, 4–8
Tollefson GD. Cognitive function in schizophrenic patients. Suppl 11, 31–39
Tondo L see Baldessarini RJ
Torch EM. Shared obsessive-compulsive disorder in a married couple: a new variant of folie à deux? [letter] Oct 489
Trivedi MH. Functional neuroanatomy of obsessive-compulsive disorder. Suppl 8, 26–35
Tugrul KC see Keck PE Jr; McElroy SL
Turret N see Nobler MS
Umbricht DSG see Ames D
Van Ameringen M see Mancini C
Vasavada N see Rush AJ
Verburg K see Pols HJ
Vuckovic A see Stoll AL
Wagner KD. Major depression and anxiety disorders associated with Norplant. Apr 152–157
Walker PW. Review of Warner R (ed): *Alternatives to the Hospital for Acute Psychiatric Treatment.* Aug 376
Walker SE see Gardner DM
Walton SA, Berk M, Brook S. Superiority of lithium over verapamil in mania: a randomized, controlled, single-blind trial. Nov 543–546
Wang D see Saxena S
Warshaw MG, Keller MB. The relationship between fluoxetine use and suicidal behavior in 654 subjects with anxiety disorders. Apr 158–166
Warshaw MG see Goldenberg IM; Mueller TI
Watson DG see Lenox RH
Watterson JM see Lenox RH

Wei F-C, Jann MW, Lin H-N, Piao-Chien C, Chang W-H. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. July 298–302
Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome of schizophrenia. Suppl 11, 53–60
Weinberger DR see Goldberg TE; Heinz A
Weiner RD, Sibert TE. Use of ECT in treatment of depression in patients with diabetes mellitus [letter with reply]. Mar 138
Weise RE. Review of Higgins GO: *Resilient Adults: Overcoming a Cruel Past.* May 229–230
Weisler RH see Sramek JJ
Weiss DS see Marmar CR
Weiss MK see Zarate CA Jr
Weissenburger JE see Rush AJ
Wesnes K see Rapeport WG; Williams SA
Wesson VA see Levitt AJ
West SA see Keck PE Jr
Westlund RE see Mauskopf JA
Westreich LM see Castañeda R
Wetzel H see Szegedi A
Wheadon DE. Reply to Gammon GD; Lane RM: Incentive bias? [letter] June 269
White K see Goldenberg IM
Wilcox CS see Feiger A
Williams SA, Wesnes K, Oliver SD, Rapeport WG. Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol. Suppl 1, 7–11
Williams SA see Rapeport WG
Wilner KD see Ziegler MG
Wilson D see Galletly C
Wilson LG see Elliott AJ
Winston A see Galynker I
Wirshing WC see Ames D
Wisselink PG see Feiger A
Witt G see Granneman GR
Wittmaack FM see Freeman EW
Woerner M see Lieberman JA
Wong CM see DeCaria CM
Workman RH see Orengo CA
Workum SB see Stoll AL
Worthington K see Ketter TA
Wroblewski BA, Joseph AB, Cornblatt RR. Antidepressant pharmacotherapy and the treatment of depression in patients with severe traumatic brain injury: a controlled, prospective study. Dec 582–587
Wu R see Marmar CR
Yesavage J. Introduction. Geropsychiatric advances: new therapies and older patients. Suppl 5, 3–4
Yonkers K see Goldenberg IM
Young LT see Joffe RT
Young SJ. Panic associated with combining fluoxetine and bupropion [letter]. Apr 177–178
Zajecka JM. The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. Suppl 2, 10–14
Zarate CA Jr, Kando JC, Tohen M, Weiss MK, Cole JO. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? Feb 67–71
Zarate CA Jr see Kando JC; Tohen M
Zarate SB see Tohen M
Zatzick D see Marmar CR
Zayas EM, Grossberg GT. Treating the agitated Alzheimer patient. Suppl 7, 46–51
Ziegler MG, Wilner KD. Sertraline does not alter the β-adrenergic blocking activity of atenolol in healthy male volunteers. Suppl 1, 12–15
Zucconi M, Ferini-Strambi L, Gambini O, Castronovo C, Galli L, Campana A, Scarone S, Smirne S. Structured psychiatric interview and ambulatory sleep monitoring in young psychophysiological insomniacs. Aug 364–370